# WEB-APPENDIX

## Table of Contents

# Search strategy

| MEDLINE | | | EMBASE | | |
|---|---|---|---|---|---|
| SEARCH LINE | SEARCH TERM | NO. HITS | SEARCH LINE | SEARCH TERM | NO. HITS |
| 1 | (stable angina and coronar$).ti,ab. | 3909 | 1 | exp coronary artery disease/ | 207562 |
| 2 | (coronary arter$ adj5 (occlu$ or lesion* or stenos?s)).ti,ab. | 18643 | 2 | exp stable angina pectoris/ | 5095 |
| 3 | angiocardiography/ and coronar$.ab. | 846 | 3 | (coronary adj artery adj disease).ti,ab. | 74206 |
| 4 | (coronary artery disease/su or coronary artery disease/th) and coronary.ti,ab. | 7705 | 4 | stable angina.ti,ab. | 8349 |
| 5 | (Coronary Stenosis/ or Coronary Angiography/) and coronary.ti,ab. | 39516 | 5 | coronary disease.ti,ab. | 14185 |
| 6 | (Angina Pectoris/th or angiography/ or *Coronary Disease/th) and coronary.ti,ab. | 12744 | 6 | coronary disease.mp. | 20231 |
| 7 | *Coronary Restenosis/pc and coronary.ti. | 506 | 7 | or/1-6 | 237321 |
| 8 | coronary.ti,ab. and (start or tosca or ravel or widest or elutes or APPLAUSE or taxus or SIRIUS or mass or SCANDSTENT or deliver or swissi or rita or gissoc or destini or SISCA or LASMAL or OCBAS or C-SIRIUS or ESIRIUS or GISSOC or PRISON or Benestent or DEBATE or toat or stop or advance or SARECCO or SICCO or MAJIC).ti. | 1258 | 8 | exp stent/ | 87732 |
| 9 | or/1-8 | 69205 | 9 | coronary artery bypass graft/ exp transluminal coronary angioplasty/ or exp carotid angioplasty/ or exp percutaneous transluminal angioplasty/ or exp percutaneous transluminal | 49876 |
| 10 | coronary artery bypass graft/ and coronar$.ti,ab. | 30219 | 10 | angioplasty balloon/ | 47048 |
| 11 | cabg.ti,ab. | 10978 | 11 | cabg.ti,ab. | 17669 |
| 12 | coronary artery bypass graft$.ti,ab. | 20933 | 12 | coronary artery bypass graft$.ti,ab. | 27139 |
| 13 | transluminal coronary angioplast$.ti,ab. | 6519 | 13 | exp angioplasty/ and coronar$.mp. | 39328 |
| 14 | (stent$ and coronar$).ti,ab. | 16043 | 14 | stent$.ti,ab. | 84551 |
| 15 | percutaneous coronary intervention*.ti,ab. | 13116 | 15 | transluminal coronary angioplast$.ti,ab. | 7826 |
| 16 | percutaneous coronary intervention/ and coronar$.ti,ab. | 297 | 16 | (coro$ adj10 angioplast$).ti,ab. | 19349 |
| 17 | (pci and coronar$).ti,ab. | 7608 | 17 | or/8-16 | 189157 |
| 18 | angioplasty/ and coronar$.ti,ab. | 856 | 18 | and/7,17 | 49999 |
| 19 | stent/ and coronar$.ti,ab. | 11948 | 19 | random$.tw. | 787541 |

| | | | | | |
|---|---|---|---|---|---|
| 20 | (coronar$ adj10 angioplas$).ti,ab. | 15162 | 20 | factorial$.tw. | 20344 |
| 21 | percutaneous transluminal angioplasty/ and coronary.ti,ab. | 854 | 21 | (crossover$ or cross-over$).tw. | 64637 |
| 22 | (ptca and coronary).ti,ab. | 5285 | 22 | placebo$.tw. | |
| 23 | or/10-22 | 69025 | 23 | (doubl$ adj blind$).tw. | 134701 |
| 24 | and/9,23 | 27443 | 24 | (singl$ adj blind$).tw. | 13083 |
| 25 | randomized controlled trial.pt. | 342617 | 25 | assign$.tw. | 217453 |
| 26 | controlled clinical trial.pt. | 85357 | 26 | allocat$.tw. | 73738 |
| 27 | randomized.ab. | 245653 | 27 | volunteer$.tw. | 165073 |
| 28 | placebo.ab. | 136033 | 28 | Crossover Procedure.sh. | 36385 |
| 29 | drug therapy.fs. | 1586538 | 29 | Double-blind Procedure.sh. | 113510 |
| 30 | randomly.ab. | 175984 | 30 | Randomized Controlled Trial.sh. | 338458 |
| 31 | trial.ab. | 252940 | 31 | Single-blind Procedure.sh. | 17091 |
| 32 | groups.ab. | 1147339 | 32 | or/19-31 | 1286191 |
| 33 | or/25-32 | 2959415 | 33 | animal/ | 1811823 |
| 34 | exp animals/ not humans.sh. | 3778609 | 34 | animal/ and human/ | 457363 |
| 35 | 33 not 34 | 2514241 | 35 | 33 not 34 | 1354460 |
| 36 | and/24,35 | 8672 | 36 | 32 not 35 | 1243535 |
| 37 | limit 36 to yr="1902 - 1979" | 91 | 37 | and/18,36 | 6721 |
| 38 | 36 not 37 | 8581 | 38 | case report.tw. | 240425 |
| 39 | remove duplicates from 38 | 8547 | 39 | letter/ | 789624 |
| 40 | case report.tw. | 171581 | 40 | or/38-39 | 1025892 |
| 41 | letter/ | 762324 | 41 | 37 not 40 | 6664 |
| 42 | historical article/ | 289893 | 42 | limit 41 to yr="2010 -Current" | 1763 |
| 43 | or/40-42 | 1213174 | 43 | remove duplicates from 42 | 1724 |
| 44 | 39 not 43 | 8413 | 44 | 41 not 42 | 4901 |
| | | | 45 | remove duplicates from 44 | 4751 |
| | | | 46 | or/43,45 | 6475 |

## Supplemental information on statistical analysis

### *Additional sensitivity analysis*

We conducted sensitivity analyses using three different versions of weakly informative priors for tau:

1. An exponential distribution with mean 1 and 2.5th and 97.5% percentiles of 0.025 and 3.69.
2. A uniform distribution between 0 and 2 and a mean of 1.
3. A half-normal distribution with a mean of 0.5 and 2.5th and 97.5% percentiles 95% from 0.02 to 1.4.

### *Construction of funnel plots*

Comparison-adjusted funnel plots to investigate the presence of small-study effects in the network meta-analysis.[101] This graph requires an assumption of how small-study effects will take place in a network meta-analysis. We assumed that treatment effect estimates influenced by small-study effects would overestimate the beneficial effect of experimental interventions. We ordered interventions from least to most experimental as follows: medical therapy, PTCA, BMS, PES, SES, EZES, RZES, EES, CABG. The horizontal axis of the graph represents the difference between the treatment effect estimate reported in a single trial and the treatment effect estimate combined across trials using a conventional pairwise fixed-effect meta-analysis for each of the head-to-head comparisons in the network with available direct evidence. Estimates are ratio of rate ratios comparing a trial's estimate with the pooled estimate from fixed-effect meta-analysis for a pairwise comparison. Estimates below one indicate that the benefit of the experimental intervention is more pronounced in the trial than the pooled estimate. Observations from small studies missing on the right side of the line of null effect (ratio of rate ratios > 1) indicate that small studies tend to exaggerate the effectiveness of experimental treatments.

**Quality Assessment**

| ITEM | DEFINITION |
|---|---|
| CONCEALMENT OF ALLOCATION | We considered allocation concealment adequate if the investigators responsible for patient selection were unable to suspect before allocation which treatment was next. Methods considered adequate included central randomisation and sequentially numbered, sealed, opaque envelopes. Concealment was downgraded to inadequate, if there was evidence of inadequate sequence generation. |
| ADJUDICATION OF OUTCOMES | We considered adjudication of outcomes to be blinded if investigators adjudicating potential clinical events were described to be blinded as to the allocated intervention. |
| ANALYSES | We considered statistical analyses to be according to the intention-to-treat principle if all randomised patients were included in the analysis in the group they were originally allocated to. |

## Supplemental Figure 1 - Identification of eligible trials




RCT=randomised controlled trial

**SUPPLEMENTAL TABLE 1** **Characteristics of Eligible Studies**

| Ref. | Study Acronym | Follow-up (months) | Mean Age (years) | Females (%) | Diabetes (%) | Multivessel Disease (%) | LV Dysfunction (%) | LVEF (mean) | Adequate allocation concealment | Blind adjudication of events | Analysis by intention-to-treat |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ADVANCE | 10 | 61.6 | 27 | 17 | 0 | --- | --- | Yes | No | No |
| 2 | ALKK | 56 | 57.8 | 13 | 16 | 0 | --- | --- | Yes | No | Yes |
| 3 | AVERT | 18 | 58.5 | 16 | 16 | 43 | 0 | 61 | No | Yes | No |
| 4 | ARTS | 60 | 61 | 23 | 17 | 99 | 0 | 60.5 | Yes | No | Yes |
| 5 | AS | 24 | 52.1 | 27 | 3 | --- | --- | --- | Yes | No | No |
| 6 | AWESOME | 36 | 67 | --- | 31 | 82 | --- | 45 | No | No | Yes |
| 7 | BARI | 65 | 61.5 | 27 | 25 | 100 | 22 | 57.3 | Yes | No | Yes |
| 8 | BARI-2D | 64 | 62 | 32 | 100 | 20 | --- | 57 | No | Yes | Yes |
| 9 | BASKET | 6 | 64 | 21 | 19 | 69 | --- | --- | Yes | Yes | Yes |
| 10 | BASKET-PROVE | 24 | 66.3 | 24 | 16 | 43 | --- | --- | Yes | Yes | Yes |
| 11 | BENESTENT-I | 60 | 57.5 | 19 | 6 | 0 | --- | --- | Yes | Yes | No |
| 12 | BENESTENT-II | 12 | 54.5 | 22 | 12 | --- | --- | --- | Yes | Yes | Yes |
| 13 | BESMART | 6 | 61.5 | 24 | 17 | 49 | --- | 62.5 | Yes | No | No |
| 14 | Boudriot et al. (2011) | 12 | 67.5 | 25 | 36 | 72 | --- | --- | No | Yes | Yes |
| 15 | CABRI | 12 | 60 | 22 | 12 | 99 | --- | 63 | Yes | No | Yes |
| 16 | CARDia | 12 | 64 | 26 | 100 | 93 | --- | --- | Yes | Yes | No |
| 17 | CASS | 64 | 51·2 | 10 | 9 | 73 | --- | --- | Yes | No | Yes |
| 18 | CEREA-DES | 12 | 63.8 | 15 | 0 | 45 | --- | 57.7 | Yes | No | Yes |
| 19 | COAST | 8 | 61.3 | 26 | 19 | 80 | --- | --- | No | No | No |
| 20 | COMPARE | 24 | 63.3 | 29 | 18 | 27 | --- | --- | Yes | Yes | Yes |
| 21 | COURAGE | 55 | 61.6 | 15 | 33 | 69 | 17 | 60.8 | No | Yes | Yes |
| 22 | Chen et al. (2009) | 8 | --- | 27 | 20 | --- | --- | --- | Yes | No | No |
| 23 | DEBATE-II | 12 | 59.2 | 27 | 10 | 10 | --- | --- | No | No | No |
| 24 | DES-DIABETES | 48 | 60.9 | 42 | 100 | 64 | 0 | 58.5 | Yes | Yes | Yes |
| 25 | E-SIRIUS | 9 | 62.3 | 29 | 23 | 36 | --- | --- | Yes | No | Yes |
| 26 | EAST | 36 | 61.6 | 26 | 23 | 100 | 0 | 61.4 | No | No | Yes |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 27 | ECSS | 60 | --- | 0 | --- | 100 | 0 | --- | No | No | No |
| 28 | ENDEAVOR II | 60 | 62 | 24 | --- | --- | 0 | --- | Yes | Yes | No |
| 29 | ENDEAVOR III | 60 | 61.5 | 31 | 29 | 39 | 0 | --- | No | Yes | No |
| 30 | ENDEAVOR IV | 60 | 63.5 | 32 | 31 | --- | 0 | --- | Yes | Yes | No |
| 31 | EPISTENT | 12 | 59.3 | 25 | 20 | --- | --- | --- | Yes | Yes | Yes |
| 32 | ERACI II | 60 | 61.9 | 21 | 17 | 100 | --- | --- | No | Yes | Yes |
| 33 | ESSENCE DIABETES | 12 | 63.3 | 41 | 100 | 55 | 0 | 60.6 | Yes | No | Yes |
| 34 | EXCELLENT | 12 | 62.7 | 35 | 38 | 52 | --- | 61.3 | Yes | Yes | No |
| 35 | FAME-II | 7 | 63.7 | 22 | 27 | 42 | 16 | --- | Yes | Yes | Yes |
| 36 | FREEDOM | 52 | 63.1 | 29 | 100 | 100 | --- | 66.2 | No | Yes | Yes |
| 37 | FROST | 6 | 59.9 | 18 | 16 | --- | 0 | --- | Yes | No | No |
| 38 | GABI | 12 | --- | 20 | 12 | 100 | --- | --- | No | No | No |
| 39 | ISAR DIABETES | 9 | 68 | 27 | 100 | --- | --- | 51 | Yes | No | Yes |
| 40 | ISAR LEFT MAIN | 24 | 69.1 | 23 | 29 | 72 | --- | 53.9 | Yes | No | No |
| 41 | ISAR-SMART | 7 | 65.7 | 23 | 25 | 80 | --- | 60.5 | Yes | No | Yes |
| 42 | ISAR-SMART 3 | 12 | 66.6 | 28 | 0 | 81 | --- | 56.3 | Yes | Yes | Yes |
| 43 | ISAR-TEST-2 | 24 | 66.9 | 24 | 27 | 84 | --- | 53.5 | Yes | Yes | Yes |
| 44 | ISAR-TEST-4 | 36 | 66.8 | 23 | 29 | 86 | --- | 53.6 | Yes | Yes | Yes |
| 45 | JSAP | 40 | 64.4 | 26 | 40 | 32 | --- | 64.9 | Yes | Yes | No |
| 46 | Kinsara et al. (2003) | 6 | 55 | 22 | 56 | 70 | --- | --- | No | No | Yes |
| 47 | LONG DES II | 9 | 61 | 36 | 33 | 63 | 0 | 58.7 | Yes | No | Yes |
| 48 | LONG DES III | 12 | 63 | 30 | 30 | 56 | 0 | 60.3 | Yes | Yes | Yes |
| 49 | LONG-DES-IV | 12 | 62.7 | 27 | 29 | 49 | 0 | 59.5 | Yes | Yes | Yes |
| 50 | MAJIC | 6 | 63.5 | 19 | 32 | 58 | --- | 54 | Yes | No | No |
| 51 | MASS-II | 60 | 60 | 31 | 29 | 100 | --- | 67.3 | No | No | Yes |
| 52 | OAT | 35 | 58.7 | 22 | 21 | --- | --- | 47.7 | Yes | Yes | Yes |
| 53 | OCTOSTENT | 12 | 59.6 | 29 | 11 | 29 | 10 | --- | Yes | Yes | Yes |
| 54 | Pache et al (2005) | 12 | 67 | 22 | 31 | 81 | --- | --- | Yes | No | Yes |
| 55 | Pan et al. (2012) | 12 | 63 | 19 | 32 | --- | --- | 59 | No | No | Yes |
| 56 | Pan et al. (2007) | 24 | 61.5 | 18 | 37 | --- | --- | 59 | No | No | Yes |
| 57 | PRECOMBAT | 24 | 62.3 | 24 | 32 | 90 | --- | 61.2 | Yes | Yes | Yes |
| 58 | PRISON | 13 | 58.1 | 22 | 12 | 43 | 20 | --- | Yes | No | Yes |
| 59 | PRISON II | 60 | 59.5 | 21 | 14 | 51 | 21 | --- | No | Yes | Yes |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 60 | PRODIGY | 24 | 67.8 | 23 | 24 | 66 | --- | 50.6 | Yes | Yes | No |
| 61 | PROTECT | 36 | 62.2 | 24 | 28 | 18 | --- | --- | Yes | Yes | Yes |
| 62 | RAVEL | 60 | 60.7 | 24 | 18 | 0 | 0 | --- | Yes | No | Yes |
| 63 | REALITY | 12 | 62.6 | 27 | 28 | 52 | --- | --- | Yes | Yes | No |
| 64 | RESET | 12 | 69.1 | 23 | 45 | 47 | 2 | --- | No | Yes | Yes |
| 65 | RESOLUTE AC | 24 | 64.3 | 23 | 23 | 59 | --- | --- | Yes | Yes | No |
| 66 | RESOLUTE CHINA | 12 | 59.6 | 21 | 28 | --- | --- | --- | Yes | Yes | No |
| 67 | RESTENOSIS STENT | 6 | 59.5 | 19 | 18 | 32 | --- | --- | No | No | No |
| 68 | RITA-I | 78 | --- | 19 | 6 | 55 | --- | --- | Yes | Yes | Yes |
| 69 | RITA-II | 60 | --- | 18 | 9 | 40 | --- | --- | Yes | Yes | Yes |
| 70 | SCANDSTENT | 36 | 62.7 | 23 | 18 | 44 | --- | 54.5 | No | Yes | No |
| 71 | SCORPIUS | 60 | 66 | 36 | 100 | --- | 0 | --- | Yes | Yes | No |
| 72 | SES SMART | 8 | 63.6 | 28 | 25 | 65 | 0 | --- | Yes | Yes | Yes |
| 73 | SIRIUS | 57 | 62.3 | 29 | 26 | 42 | 0 | 56 | Yes | Yes | No |
| 74 | SIRTAX | 60 | 62 | 23 | 20 | 59 | --- | 57 | Yes | Yes | Yes |
| 75 | SISA | 6 | 60.2 | 33 | 19 | 0 | 0 | 63.6 | No | No | Yes |
| 76 | SORT OUT II | 18 | 63.6 | 26 | 14 | 21 | --- | --- | No | Yes | Yes |
| 77 | SORT OUT III | 36 | 64.3 | 27 | 14 | 30 | --- | --- | Yes | Yes | Yes |
| 78 | SORT-OUT IV | 24 | 64.1 | 30 | 17 | 19 | --- | --- | Yes | Yes | Yes |
| 79 | SPIRIT III | 36 | 63.1 | 31 | 29 | --- | 0 | --- | Yes | Yes | No |
| 80 | SPIRIT-II | 60 | 62 | 27 | 23 | --- | --- | --- | Yes | Yes | Yes |
| 81 | SPIRIT-IV | 24 | 63.3 | 32 | 32 | 25 | --- | --- | Yes | Yes | Yes |
| 82 | SPIRIT-V | 12 | 65.3 | 31 | 100 | --- | --- | --- | Yes | No | No |
| 83 | START | 52 | 59 | 14 | 13 | 35 | --- | 61 | Yes | No | No |
| 84 | STICH | 56 | --- | 12 | 39 | --- | 100 | --- | Yes | Yes | Yes |
| 85 | STRESS | 12 | 60 | 22 | 15 | 34 | --- | 61 | Yes | No | No |
| 86 | SWISSI-II | 122 | 55.3 | 12 | 11 | --- | --- | 56.9 | Yes | Yes | Yes |
| 87 | SYNTAX | 60 | 65.1 | 22 | 25 | 100 | --- | --- | Yes | No | Yes |
| 88 | SoS | 72 | 61 | 21 | 14 | 100 | --- | --- | Yes | Yes | No |
| 89 | TAXUS IV | 60 | 62.4 | 28 | 24 | 19 | 0 | 55.3 | Yes | Yes | No |
| 90 | TAXUS-II | 60 | 60.4 | 25 | 14 | --- | --- | --- | No | Yes | Yes |
| 91 | TAXUS-V | 9 | 62.9 | 31 | 31 | --- | --- | --- | Yes | Yes | No |
| 92 | TAXi | 37 | 64 | 20 | 34 | 61 | --- | --- | No | No | Yes |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 93 | TOSCA | 12 | 57.6 | 18 | 17 | --- | --- | 60 | No | No | Yes |
| 94 | TWENTE | 12 | 64.2 | 28 | 22 | --- | 2 | --- | Yes | Yes | No |
| 95 | Thiele et al. (2005) | 67 | 62 | 25 | 30 | --- | --- | 62.5 | Yes | No | No |
| 96 | VA | 60 | --- | --- | --- | 86 | --- | --- | No | No | Yes |
| 97 | VA-ACME | 36 | 60 | --- | 18 | 0 | 10 | 68 | No | No | Yes |
| 98 | WIDEST | 12 | 58.2 | 24 | 8 | 0 | --- | --- | Yes | No | Yes |
| 99 | ZEST | 12 | 61.9 | 33 | 29 | 47 | 0 | 61 | Yes | Yes | Yes |
| 100 | Zhang et al. (2006) | 12 | 64.3 | 31 | 27 | 56 | 0 | --- | No | No | No |

Ref.: References, LVEF: Left ventricular ejection fraction, LV: Left ventricle

**Supplemental Table 2** **Numbers of primary and secondary outcomes per trial**

| Ref. | Study Acronym | Outcome | Medical Therapy | | CABG | | PTCA | | BMS | | PES | | SES | | E-ZES | | R-ZES | | EES | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Events | Patient Years | Events | Patient Years | Events | Patient Years | Events | Patient Years | Events | Patient Years | Events | Patient Years | Events | Patient Years | Events | Patient Years | Events | Patient Years |
| 1 | ADVANCE | MI | --- | --- | --- | --- | 7 | 119 | 4 | 121 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | ADVANCE | Revasc | --- | --- | --- | --- | 21 | 119 | 26 | 121 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2 | ALKK | Death | 17 | 705 | --- | --- | 6 | 695 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2 | ALKK | MI | 12 | 705 | --- | --- | 10 | 695 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2 | ALKK | Death or MI | 29 | 705 | --- | --- | 16 | 695 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2 | ALKK | Revasc | 36 | 705 | --- | --- | 25 | 695 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 3 | ART | MI | 4 | 246 | --- | --- | 5 | 266 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 3 | ART | Revasc | 20 | 246 | --- | --- | 29 | 266 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 4 | ARTS | Death | --- | --- | 46 | 3025 | --- | --- | 48 | 3000 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 4 | ARTS | MI | --- | --- | 39 | 3025 | --- | --- | 51 | 3000 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 4 | ARTS | Death or MI | --- | --- | 85 | 3025 | --- | --- | 99 | 3000 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 4 | ARTS | Revasc | --- | --- | 53 | 3025 | --- | --- | 182 | 3000 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 5 | AS | Death | --- | --- | --- | --- | 0 | 392 | 1 | 384 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 5 | AS | MI | --- | --- | --- | --- | 4 | 392 | 4 | 384 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 5 | AS | Death or MI | --- | --- | --- | --- | 4 | 392 | 5 | 384 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 5 | AS | Revasc | --- | --- | --- | --- | 50 | 392 | 33 | 384 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 6 | AWESOME | Death | --- | --- | 49 | 696 | --- | --- | 44 | 666 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 6 | AWESOME | Revasc | --- | --- | 4 | 19 | --- | --- | 14 | 19 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 7 | BARI | Death | --- | --- | 111 | 4570 | 131 | 4575 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 7 | BARI | MI | --- | --- | 107 | 4570 | 100 | 4575 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 7 | BARI | Death or MI | --- | --- | 218 | 4570 | 231 | 4575 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 7 | BARI | Revasc | --- | --- | 73 | 4570 | 499 | 4575 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 8 | BARI-2D | Death | 96 | 4035 | --- | --- | --- | --- | 102 | 3990 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 8 | BARI-2D | Death | 65 | 1925 | 53 | 1890 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 8 | BARI-2D | MI | 88 | 4035 | --- | --- | --- | --- | 95 | 3990 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8 | BARI-2D | MI | 63 | 1925 | 33 | 1890 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 8 | BARI-2D | Death or MI | 157 | 4035 | --- | --- | --- | --- | 173 | 3990 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 8 | BARI-2D | Death or MI | 109 | 1925 | 74 | 1890 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 8 | BARI-2D | Revasc | 315 | 4030 | --- | --- | --- | --- | 213 | 3980 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 8 | BARI-2D | Revasc | 137 | 1925 | 27 | 1885 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 9 | BASKET | Death | --- | --- | --- | --- | --- | --- | 9 | 140 | 7 | 141 | 5 | 132 | --- | --- | --- | --- | --- | --- |
| 9 | BASKET | MI | --- | --- | --- | --- | --- | --- | 12 | 140 | 6 | 141 | 6 | 132 | --- | --- | --- | --- | --- | --- |
| 9 | BASKET | Death or MI | --- | --- | --- | --- | --- | --- | 21 | 140 | 13 | 141 | 11 | 132 | --- | --- | --- | --- | --- | --- |
| 9 | BASKET | Revasc | --- | --- | --- | --- | --- | --- | 22 | 140 | 17 | 141 | 8 | 132 | --- | --- | --- | --- | --- | --- |
| 10 | BASKET-PROVE | Death | --- | --- | --- | --- | --- | --- | 34 | 1530 | --- | --- | 28 | 1550 | --- | --- | --- | --- | 25 | 1548 |
| 10 | BASKET-PROVE | MI | --- | --- | --- | --- | --- | --- | 20 | 1530 | --- | --- | 7 | 1550 | --- | --- | --- | --- | 13 | 1548 |
| 10 | BASKET-PROVE | Death or MI | --- | --- | --- | --- | --- | --- | 54 | 1530 | --- | --- | 35 | 1550 | --- | --- | --- | --- | 38 | 1548 |
| 10 | BASKET-PROVE | Revasc | --- | --- | --- | --- | --- | --- | 79 | 1530 | --- | --- | 33 | 1550 | --- | --- | --- | --- | 29 | 1548 |
| 12 | BENESTENT-II | Death | --- | --- | --- | --- | 4 | 413 | 4 | 414 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 12 | BENESTENT-II | MI | --- | --- | --- | --- | 19 | 413 | 14 | 414 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 12 | BENESTENT-II | Death or MI | --- | --- | --- | --- | 23 | 413 | 18 | 414 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 12 | BENESTENT-II | Revasc | --- | --- | --- | --- | 82 | 413 | 59 | 414 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 13 | BESMART | Death | --- | --- | --- | --- | 4 | 83 | 1 | 88 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 13 | BESMART | MI | --- | --- | --- | --- | 2 | 83 | 1 | 88 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 13 | BESMART | Death or MI | --- | --- | --- | --- | 6 | 83 | 2 | 88 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 13 | BESMART | Revasc | --- | --- | --- | --- | 41 | 83 | 23 | 88 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 14 | Boudriot et al. (2012) | Death | --- | --- | 5 | 101 | --- | --- | --- | --- | --- | --- | 2 | 100 | --- | --- | --- | --- | --- | --- |
| 14 | Boudriot et al. (2012) | MI | --- | --- | 3 | 101 | --- | --- | --- | --- | --- | --- | 3 | 100 | --- | --- | --- | --- | --- | --- |
| 14 | Boudriot et al. (2012) | Death or MI | --- | --- | 8 | 101 | --- | --- | --- | --- | --- | --- | 5 | 100 | --- | --- | --- | --- | --- | --- |
| 14 | Boudriot et al. (2012) | Revasc | --- | --- | 6 | 101 | --- | --- | --- | --- | --- | --- | 14 | 100 | --- | --- | --- | --- | --- | --- |
| 15 | CABRI | Death | --- | --- | 14 | 513 | 21 | 541 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 15 | CABRI | MI | --- | --- | 18 | 513 | 27 | 541 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 15 | CABRI | Death or MI | --- | --- | 32 | 513 | 48 | 541 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 15 | CABRI | Revasc | --- | --- | 18 | 513 | 198 | 541 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 16 | CARDia | Death | --- | --- | 8 | 248 | --- | --- | --- | --- | --- | --- | 8 | 254 | --- | --- | --- | --- | --- | --- |
| 16 | CARDia | MI | --- | --- | 14 | 248 | --- | --- | --- | --- | --- | --- | 25 | 254 | --- | --- | --- | --- | --- | --- |
| 16 | CARDia | Death or MI | --- | --- | 22 | 248 | --- | --- | --- | --- | --- | --- | 33 | 254 | --- | --- | --- | --- | --- | --- |
| 16 | CARDia | Revasc | --- | --- | 5 | 248 | --- | --- | --- | --- | --- | --- | 30 | 254 | --- | --- | --- | --- | --- | --- |

| | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17 | CASS | Death | 36 | 2080 | 29 | 2080 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 18 | CEREA-DES | Death | --- | --- | --- | --- | --- | --- | 1 | 250 | 0 | 125 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 18 | CEREA-DES | MI | --- | --- | --- | --- | --- | --- | 5 | 250 | 1 | 125 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 18 | CEREA-DES | Death or MI | --- | --- | --- | --- | --- | --- | 6 | 250 | 1 | 125 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 18 | CEREA-DES | Revasc | --- | --- | --- | --- | --- | --- | 33 | 250 | 13 | 125 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 22 | Chen | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 13 | 71 | 1 | 75 | --- | --- | --- | --- | --- | --- | --- |
| 19 | COAST | Death | --- | --- | --- | --- | 0 | 135 | 4 | 272 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 19 | COAST | MI | --- | --- | --- | --- | 2 | 135 | 2 | 272 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 19 | COAST | Death or MI | --- | --- | --- | --- | 2 | 135 | 6 | 272 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 19 | COAST | Revasc | --- | --- | --- | --- | 28 | 135 | 42 | 272 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 20 | COMPARE | Death | --- | --- | --- | --- | --- | --- | --- | --- | 27 | 1806 | --- | --- | --- | --- | --- | --- | 30 | 1794 | |
| 20 | COMPARE | MI | --- | --- | --- | --- | --- | --- | --- | --- | 68 | 1806 | --- | --- | --- | --- | --- | --- | 35 | 1794 | |
| 20 | COMPARE | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 93 | 1806 | --- | --- | --- | --- | --- | --- | 63 | 1794 | |
| 20 | COMPARE | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 69 | 1806 | --- | --- | --- | --- | --- | --- | 27 | 1794 | |
| 21 | COURAGE | Death | 95 | 5235 | --- | --- | --- | --- | 85 | 5285 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 21 | COURAGE | MI | 126 | 5235 | --- | --- | --- | --- | 147 | 5285 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 21 | COURAGE | Death or MI | 202 | 5235 | --- | --- | --- | --- | 211 | 5285 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 21 | COURAGE | Revasc | 348 | 5235 | --- | --- | --- | --- | 228 | 5285 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 23 | DEBATE-II | Death | --- | --- | --- | --- | 4 | 258 | 6 | 351 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 23 | DEBATE-II | MI | --- | --- | --- | --- | 10 | 258 | 13 | 351 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 23 | DEBATE-II | Death or MI | --- | --- | --- | --- | 14 | 258 | 19 | 351 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 23 | DEBATE-II | Revasc | --- | --- | --- | --- | 40 | 258 | 25 | 351 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 24 | DES-DIABETES | Death | --- | --- | --- | --- | --- | --- | --- | --- | 10 | 800 | 6 | 800 | --- | --- | --- | --- | --- | --- | --- |
| 24 | DES-DIABETES | MI | --- | --- | --- | --- | --- | --- | --- | --- | 2 | 800 | 3 | 800 | --- | --- | --- | --- | --- | --- | --- |
| 24 | DES-DIABETES | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 12 | 800 | 9 | 800 | --- | --- | --- | --- | --- | --- | --- |
| 24 | DES-DIABETES | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 24 | 800 | 16 | 800 | --- | --- | --- | --- | --- | --- | --- |
| 26 | EAST | Death | --- | --- | 12 | 582 | 14 | 594 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 26 | EAST | MI | --- | --- | 38 | 582 | 29 | 594 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 26 | EAST | Death or MI | --- | --- | 50 | 582 | 43 | 594 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 26 | EAST | Revasc | --- | --- | 25 | 582 | 107 | 594 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 27 | ECSS | Death | 61 | 1865 | 30 | 1970 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 28 | ENDEAVOR II | Death | --- | --- | --- | --- | --- | --- | 44 | 2910 | --- | --- | --- | --- | 36 | 2885 | --- | --- | --- | --- | --- |
| 28 | ENDEAVOR II | MI | --- | --- | --- | --- | --- | --- | 28 | 2910 | --- | --- | --- | --- | 22 | 2885 | --- | --- | --- | --- | --- |

| | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28 | ENDEAVOR II | Death or MI | --- | --- | --- | --- | --- | --- | 54 | 2396 | --- | --- | --- | --- | 47 | 2392 | --- | --- | --- | --- |
| 28 | ENDEAVOR II | Revasc | --- | --- | --- | --- | --- | --- | 117 | 2910 | --- | --- | --- | --- | 62 | 2885 | --- | --- | --- | --- |
| 29 | ENDEAVOR III | Death | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 14 | 540 | 16 | 1535 | --- | --- | --- | --- |
| 29 | ENDEAVOR III | MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 5 | 540 | 3 | 1535 | --- | --- | --- | --- |
| 29 | ENDEAVOR III | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 19 | 540 | 19 | 1535 | --- | --- | --- | --- |
| 29 | ENDEAVOR III | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 14 | 540 | 52 | 1535 | --- | --- | --- | --- |
| 30 | ENDEAVOR IV | Death | --- | --- | --- | --- | --- | --- | --- | --- | 65 | 3590 | --- | --- | 72 | 3610 | --- | --- | --- | --- |
| 30 | ENDEAVOR IV | MI | --- | --- | --- | --- | --- | --- | --- | --- | 43 | 3590 | --- | --- | 19 | 3610 | --- | --- | --- | --- |
| 30 | ENDEAVOR IV | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 48 | 1478 | --- | --- | 37 | 1484 | --- | --- | --- | --- |
| 30 | ENDEAVOR IV | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 108 | 3590 | --- | --- | 92 | 3610 | --- | --- | --- | --- |
| 31 | EPISTENT | Death | --- | --- | --- | --- | 17 | 796 | 27 | 1603 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 31 | EPISTENT | MI | --- | --- | --- | --- | 61 | 796 | 138 | 1603 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 31 | EPISTENT | Death or MI | --- | --- | --- | --- | 71 | 796 | 160 | 1603 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 31 | EPISTENT | Revasc | --- | --- | --- | --- | 159 | 796 | 247 | 1603 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 32 | ERACI II | Death | --- | --- | 26 | 1125 | --- | --- | 16 | 1125 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 32 | ERACI II | MI | --- | --- | 14 | 1125 | --- | --- | 6 | 1125 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 32 | ERACI II | Death or MI | --- | --- | 40 | 1125 | --- | --- | 22 | 1125 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 32 | ERACI II | Revasc | --- | --- | 17 | 1125 | --- | --- | 64 | 1125 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 25 | E-SIRIUS | Death | --- | --- | --- | --- | --- | --- | 1 | 133 | --- | --- | 2 | 131 | --- | --- | --- | --- | --- | --- |
| 25 | E-SIRIUS | MI | --- | --- | --- | --- | --- | --- | 4 | 133 | --- | --- | 8 | 131 | --- | --- | --- | --- | --- | --- |
| 25 | E-SIRIUS | Death or MI | --- | --- | --- | --- | --- | --- | 5 | 133 | --- | --- | 9 | 131 | --- | --- | --- | --- | --- | --- |
| 25 | E-SIRIUS | Revasc | --- | --- | --- | --- | --- | --- | 37 | 133 | --- | --- | 7 | 131 | --- | --- | --- | --- | --- | --- |
| 33 | ESSENCE DIABETES | Death | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 5 | 151 | --- | --- | --- | --- | 2 | 149 |
| 33 | ESSENCE DIABETES | MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 2 | 151 | --- | --- | --- | --- | 0 | 149 |
| 33 | ESSENCE DIABETES | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 7 | 151 | --- | --- | --- | --- | 2 | 149 |
| 33 | ESSENCE DIABETES | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 6 | 151 | --- | --- | --- | --- | 1 | 149 |
| 34 | EXCELLENT | Death | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 4 | 361 | --- | --- | --- | --- | 7 | 1067 |
| 34 | EXCELLENT | MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 5 | 361 | --- | --- | --- | --- | 15 | 1067 |
| 34 | EXCELLENT | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 9 | 361 | --- | --- | --- | --- | 22 | 1067 |
| 34 | EXCELLENT | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 8 | 361 | --- | --- | --- | --- | 33 | 1067 |
| 35 | FAME-II | Death | 3 | 261 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 1 | 264 |
| 35 | FAME-II | MI | 14 | 261 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 15 | 264 |
| 35 | FAME-II | Death or MI | 17 | 261 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 15 | 264 |

| | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 35 | FAME-II | Revasc | 86 | 261 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 14 | 264 |
| 36 | FREEDOM | Death | --- | --- | 83 | 4735 | --- | --- | --- | --- | --- | --- | 114 | 4765 | --- | --- | --- | --- | --- | --- |
| 36 | FREEDOM | MI | --- | --- | 48 | 4735 | --- | --- | --- | --- | --- | --- | 98 | 4765 | --- | --- | --- | --- | --- | --- |
| 36 | FREEDOM | Death or MI | --- | --- | 131 | 4735 | --- | --- | --- | --- | --- | --- | 212 | 4765 | --- | --- | --- | --- | --- | --- |
| 36 | FREEDOM | Revasc | --- | --- | 42 | 947 | --- | --- | --- | --- | --- | --- | 117 | 953 | --- | --- | --- | --- | --- | --- |
| 37 | FROST | Death | --- | --- | --- | --- | 0 | 63 | 3 | 63 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 37 | FROST | MI | --- | --- | --- | --- | 1 | 63 | 2 | 63 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 37 | FROST | Death or MI | --- | --- | --- | --- | 1 | 63 | 5 | 63 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 37 | FROST | Revasc | --- | --- | --- | --- | 19 | 63 | 18 | 63 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 38 | GABI | Death | --- | --- | 9 | 139 | 4 | 155 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 38 | GABI | MI | --- | --- | 13 | 139 | 7 | 155 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 38 | GABI | Death or MI | --- | --- | 22 | 139 | 11 | 155 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 38 | GABI | Revasc | --- | --- | 8 | 139 | 68 | 155 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 39 | ISAR DIABETES | Death | --- | --- | --- | --- | --- | --- | --- | --- | 6 | 94 | 4 | 94 | --- | --- | --- | --- | --- | --- |
| 39 | ISAR DIABETES | MI | --- | --- | --- | --- | --- | --- | --- | --- | 3 | 94 | 5 | 94 | --- | --- | --- | --- | --- | --- |
| 39 | ISAR DIABETES | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 9 | 94 | 9 | 94 | --- | --- | --- | --- | --- | --- |
| 39 | ISAR DIABETES | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 15 | 94 | 8 | 94 | --- | --- | --- | --- | --- | --- |
| 40 | ISAR LEFT MAIN | Death | --- | --- | --- | --- | --- | --- | --- | --- | 28 | 604 | 25 | 610 | --- | --- | --- | --- | --- | --- |
| 40 | ISAR LEFT MAIN | MI | --- | --- | --- | --- | --- | --- | --- | --- | 16 | 604 | 14 | 610 | --- | --- | --- | --- | --- | --- |
| 40 | ISAR LEFT MAIN | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 40 | 604 | 34 | 610 | --- | --- | --- | --- | --- | --- |
| 40 | ISAR LEFT MAIN | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 25 | 604 | 30 | 610 | --- | --- | --- | --- | --- | --- |
| 41 | ISAR-SMART | Death | --- | --- | --- | --- | 3 | 117 | 2 | 119 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 41 | ISAR-SMART | Revasc | --- | --- | --- | --- | 33 | 117 | 41 | 119 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 42 | ISAR-SMART 3 | Death | --- | --- | --- | --- | --- | --- | --- | --- | 4 | 180 | 3 | 180 | --- | --- | --- | --- | --- | --- |
| 42 | ISAR-SMART 3 | MI | --- | --- | --- | --- | --- | --- | --- | --- | 6 | 180 | 7 | 180 | --- | --- | --- | --- | --- | --- |
| 42 | ISAR-SMART 3 | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 10 | 180 | 9 | 180 | --- | --- | --- | --- | --- | --- |
| 43 | ISAR-TEST-2 | Death | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 18 | 670 | 21 | 678 | --- | --- | --- | --- |
| 43 | ISAR-TEST-2 | MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 18 | 670 | 13 | 678 | --- | --- | --- | --- |
| 43 | ISAR-TEST-2 | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 34 | 670 | 31 | 678 | --- | --- | --- | --- |
| 44 | ISAR-TEST-4 | Death | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 65 | 1956 | --- | --- | --- | --- | 58 | 1956 |
| 44 | ISAR-TEST-4 | MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 34 | 1956 | --- | --- | --- | --- | 31 | 1956 |
| 44 | ISAR-TEST-4 | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 99 | 1956 | --- | --- | --- | --- | 89 | 1956 |
| 44 | ISAR-TEST-4 | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 147 | 1956 | --- | --- | --- | --- | 132 | 1956 |

| | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45 | JSAP | Death | 7 | 630 | --- | --- | --- | --- | 5 | 620 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 45 | JSAP | MI | 7 | 630 | --- | --- | --- | --- | 3 | 620 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 45 | JSAP | Death or MI | 14 | 630 | --- | --- | --- | --- | 8 | 620 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 45 | JSAP | Revasc | 70 | 634 | --- | --- | --- | --- | 41 | 634 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 46 | Kinsara et al (2003) | Death | --- | --- | --- | --- | 0 | 53 | 1 | 48 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 46 | Kinsara et al (2003) | MI | --- | --- | --- | --- | 7 | 53 | 6 | 48 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 46 | Kinsara et al (2003) | Death or MI | --- | --- | --- | --- | 7 | 53 | 7 | 48 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 46 | Kinsara et al (2003) | Revasc | --- | --- | --- | --- | 25 | 53 | 12 | 48 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 47 | LONG DES II | Death | --- | --- | --- | --- | --- | --- | --- | --- | 0 | 188 | 2 | 188 | --- | --- | --- | --- | --- | --- |
| 47 | LONG DES II | MI | --- | --- | --- | --- | --- | --- | --- | --- | 27 | 188 | 22 | 188 | --- | --- | --- | --- | --- | --- |
| 47 | LONG DES II | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 27 | 188 | 24 | 188 | --- | --- | --- | --- | --- | --- |
| 47 | LONG DES II | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 18 | 188 | 6 | 188 | --- | --- | --- | --- | --- | --- |
| 48 | LONG DES III | Death | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 0 | 226 | --- | --- | --- | --- | 1 | 224 |
| 48 | LONG DES III | MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 18 | 226 | --- | --- | --- | --- | 22 | 224 |
| 48 | LONG DES III | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 18 | 226 | --- | --- | --- | --- | 23 | 224 |
| 48 | LONG DES III | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 6 | 226 | --- | --- | --- | --- | 9 | 224 |
| 49 | LONG-DES-IV | Death | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 2 | 250 | 4 | 250 | --- | --- |
| 49 | LONG-DES-IV | MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 29 | 250 | 34 | 250 | --- | --- |
| 49 | LONG-DES-IV | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 31 | 250 | 35 | 250 | --- | --- |
| 49 | LONG-DES-IV | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 5 | 250 | 6 | 250 | --- | --- |
| 50 | MAJIC | MI | --- | --- | --- | --- | 0 | 55 | 0 | 54 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 50 | MAJIC | Revasc | --- | --- | --- | --- | 54 | 55 | 33 | 54 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 51 | MASS-II | Death | 33 | 1015 | 26 | 1015 | --- | --- | 32 | 1025 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 51 | MASS-II | MI | 31 | 1015 | 17 | 1015 | --- | --- | 23 | 1025 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 51 | MASS-II | Death or MI | 64 | 1015 | 43 | 1015 | --- | --- | 55 | 1025 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 51 | MASS-II | Revasc | 49 | 1015 | 7 | 1015 | --- | --- | 66 | 1025 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 52 | OAT | Death | 84 | 4336 | --- | --- | --- | --- | 87 | 4328 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 52 | OAT | MI | 44 | 4336 | --- | --- | --- | --- | 59 | 4328 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 52 | OAT | Death or MI | 116 | 4336 | --- | --- | --- | --- | 139 | 4328 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 52 | OAT | Revasc | 205 | 4336 | --- | --- | --- | --- | 170 | 4328 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 53 | OCTOSTENT | Death | --- | --- | 4 | 142 | --- | --- | 0 | 138 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 53 | OCTOSTENT | MI | --- | --- | 7 | 142 | --- | --- | 6 | 138 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 53 | OCTOSTENT | Death or MI | --- | --- | 11 | 142 | --- | --- | 6 | 138 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53 | OCTOSTENT | Revasc | --- | --- | 5 | 142 | --- | --- | 17 | 138 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 54 | Pache et al (2005) | Death | --- | --- | --- | --- | --- | --- | 5 | 250 | --- | --- | 7 | 250 | --- | --- | --- | --- | --- | --- |
| 54 | Pache et al (2005) | Death or MI | --- | --- | --- | --- | --- | --- | 12 | 250 | --- | --- | 18 | 250 | --- | --- | --- | --- | --- | --- |
| 54 | Pache et al (2005) | Revasc | --- | --- | --- | --- | --- | --- | 47 | 250 | --- | --- | 18 | 250 | --- | --- | --- | --- | --- | --- |
| 55 | Pan et al (2012) | Death | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 4 | 145 | --- | --- | --- | --- | 1 | 148 |
| 55 | Pan et al (2012) | MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 4 | 145 | --- | --- | --- | --- | 2 | 148 |
| 55 | Pan et al (2012) | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 8 | 145 | --- | --- | --- | --- | 3 | 148 |
| 55 | Pan et al (2012) | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 4 | 145 | --- | --- | --- | --- | 5 | 148 |
| 56 | Pan et al (2007) | Death | --- | --- | --- | --- | --- | --- | --- | --- | 3 | 204 | 2 | 206 | --- | --- | --- | --- | --- | --- |
| 56 | Pan et al (2007) | MI | --- | --- | --- | --- | --- | --- | --- | --- | 2 | 204 | 2 | 206 | --- | --- | --- | --- | --- | --- |
| 56 | Pan et al (2007) | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 5 | 204 | 4 | 206 | --- | --- | --- | --- | --- | --- |
| 56 | Pan et al (2007) | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 13 | 204 | 4 | 206 | --- | --- | --- | --- | --- | --- |
| 57 | PRECOMBAT | Death | --- | --- | 10 | 600 | --- | --- | --- | --- | --- | --- | 7 | 600 | --- | --- | --- | --- | --- | --- |
| 57 | PRECOMBAT | MI | --- | --- | 3 | 600 | --- | --- | --- | --- | --- | --- | 5 | 600 | --- | --- | --- | --- | --- | --- |
| 57 | PRECOMBAT | Death or MI | --- | --- | 13 | 600 | --- | --- | --- | --- | --- | --- | 12 | 600 | --- | --- | --- | --- | --- | --- |
| 57 | PRECOMBAT | Revasc | --- | --- | 12 | 600 | --- | --- | --- | --- | --- | --- | 26 | 600 | --- | --- | --- | --- | --- | --- |
| 58 | PRISON | Death | --- | --- | --- | --- | 1 | 100 | 1 | 100 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 58 | PRISON | MI | --- | --- | --- | --- | 1 | 100 | 3 | 100 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 58 | PRISON | Death or MI | --- | --- | --- | --- | 2 | 100 | 4 | 100 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 58 | PRISON | Revasc | --- | --- | --- | --- | 29 | 100 | 13 | 100 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 59 | PRISON II | Death | --- | --- | --- | --- | --- | --- | 5 | 500 | --- | --- | 5 | 500 | --- | --- | --- | --- | --- | --- |
| 59 | PRISON II | MI | --- | --- | --- | --- | --- | --- | 7 | 500 | --- | --- | 8 | 500 | --- | --- | --- | --- | --- | --- |
| 59 | PRISON II | Death or MI | --- | --- | --- | --- | --- | --- | 12 | 500 | --- | --- | 13 | 500 | --- | --- | --- | --- | --- | --- |
| 59 | PRISON II | Revasc | --- | --- | --- | --- | --- | --- | 34 | 500 | --- | --- | 17 | 500 | --- | --- | --- | --- | --- | --- |
| 60 | PRODIGY | Death | --- | --- | --- | --- | --- | --- | 36 | 984 | 39 | 980 | --- | --- | 28 | 986 | --- | --- | 27 | 990 |
| 60 | PRODIGY | MI | --- | --- | --- | --- | --- | --- | 29 | 984 | 23 | 980 | --- | --- | 16 | 986 | --- | --- | 12 | 990 |
| 60 | PRODIGY | Death or MI | --- | --- | --- | --- | --- | --- | 55 | 984 | 53 | 980 | --- | --- | 39 | 986 | --- | --- | 35 | 990 |
| 61 | PROTECT | Death | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 186 | 13056 | 181 | 13071 | --- | --- | --- | --- |
| 61 | PROTECT | MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 628 | 13056 | 625 | 13071 | --- | --- | --- | --- |
| 61 | PROTECT | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 360 | 13056 | 331 | 13071 | --- | --- | --- | --- |
| 61 | PROTECT | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 310 | 13056 | 364 | 13071 | --- | --- | --- | --- |
| 62 | RAVEL | Death | --- | --- | --- | --- | --- | --- | 8 | 590 | --- | --- | 14 | 600 | --- | --- | --- | --- | --- | --- |
| 62 | RAVEL | MI | --- | --- | --- | --- | --- | --- | 8 | 590 | --- | --- | 10 | 600 | --- | --- | --- | --- | --- | --- |

| | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62 | RAVEL | Death or MI | --- | --- | --- | --- | --- | --- | 16 | 590 | --- | --- | 22 | 600 | --- | --- | --- | --- | --- | --- |
| 62 | RAVEL | Revasc | --- | --- | --- | --- | --- | --- | 30 | 590 | --- | --- | 11 | 600 | --- | --- | --- | --- | --- | --- |
| 63 | REALITY | Death | --- | --- | --- | --- | --- | --- | --- | --- | 9 | 669 | 16 | 684 | --- | --- | --- | --- | --- | --- |
| 63 | REALITY | MI | --- | --- | --- | --- | --- | --- | --- | --- | 40 | 669 | 35 | 684 | --- | --- | --- | --- | --- | --- |
| 63 | REALITY | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 49 | 669 | 51 | 684 | --- | --- | --- | --- | --- | --- |
| 63 | REALITY | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 12 | 669 | 14 | 684 | --- | --- | --- | --- | --- | --- |
| 64 | RESET | Death | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 40 | 1600 | --- | --- | --- | --- | 30 | 1597 |
| 64 | RESET | MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 55 | 1600 | --- | --- | --- | --- | 47 | 1597 |
| 64 | RESET | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 89 | 1600 | --- | --- | --- | --- | 70 | 1597 |
| 64 | RESET | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 106 | 1600 | --- | --- | --- | --- | 105 | 1597 |
| 65 | RESOLUTE AC | Death | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 36 | 2242 | 45 | 2256 |
| 65 | RESOLUTE AC | MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 62 | 2242 | 56 | 2256 |
| 65 | RESOLUTE AC | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 93 | 2242 | 95 | 2256 |
| 65 | RESOLUTE AC | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 112 | 2242 | 103 | 2256 |
| 66 | RESOLUTE CHINA | Death | --- | --- | --- | --- | --- | --- | --- | --- | 2 | 200 | --- | --- | --- | --- | 2 | 197 | --- | --- |
| 66 | RESOLUTE CHINA | MI | --- | --- | --- | --- | --- | --- | --- | --- | 8 | 200 | --- | --- | --- | --- | 7 | 197 | --- | --- |
| 66 | RESOLUTE CHINA | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 10 | 200 | --- | --- | --- | --- | 9 | 197 | --- | --- |
| 66 | RESOLUTE CHINA | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 18 | 200 | --- | --- | --- | --- | 4 | 197 | --- | --- |
| 67 | RESTENOSIS STENT | Death | --- | --- | --- | --- | 2 | 88 | 2 | 89 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 67 | RESTENOSIS STENT | MI | --- | --- | --- | --- | 2 | 88 | 8 | 89 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 67 | RESTENOSIS STENT | Death or MI | --- | --- | --- | --- | 4 | 88 | 10 | 89 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 67 | RESTENOSIS STENT | Revasc | --- | --- | --- | --- | 42 | 79 | 16 | 78 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 68 | RITA-I | Death | --- | --- | 45 | 3257 | 39 | 3315 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 68 | RITA-I | MI | --- | --- | 37 | 3257 | 55 | 3315 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 68 | RITA-I | Death or MI | --- | --- | 80 | 3257 | 87 | 3315 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 68 | RITA-I | Revasc | --- | --- | 54 | 3257 | 226 | 3315 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 69 | RITA-II | Death | 24 | 2570 | --- | --- | 23 | 2520 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 69 | RITA-II | MI | 23 | 3598 | --- | --- | 32 | 3528 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 69 | RITA-II | Death or MI | 39 | 2570 | --- | --- | 47 | 2520 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 69 | RITA-II | Revasc | 148 | 2570 | --- | --- | 117 | 2520 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 70 | SCANDSTENT | Death | --- | --- | --- | --- | --- | --- | 3 | 471 | --- | --- | 9 | 486 | --- | --- | --- | --- | --- | --- |
| 70 | SCANDSTENT | MI | --- | --- | --- | --- | --- | --- | 15 | 471 | --- | --- | 6 | 486 | --- | --- | --- | --- | --- | --- |
| 70 | SCANDSTENT | Death or MI | --- | --- | --- | --- | --- | --- | 18 | 471 | --- | --- | 15 | 486 | --- | --- | --- | --- | --- | --- |

| | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 70 | SCANDSTENT | Revasc | --- | --- | --- | --- | --- | --- | 54 | 471 | --- | --- | 13 | 486 | --- | --- | --- | --- | --- | --- |
| 71 | SCORPIUS | Death | --- | --- | --- | --- | --- | --- | 20 | 475 | --- | --- | 20 | 475 | --- | --- | --- | --- | --- | --- |
| 71 | SCORPIUS | MI | --- | --- | --- | --- | --- | --- | 9 | 475 | --- | --- | 8 | 475 | --- | --- | --- | --- | --- | --- |
| 71 | SCORPIUS | Death or MI | --- | --- | --- | --- | --- | --- | 29 | 475 | --- | --- | 28 | 475 | --- | --- | --- | --- | --- | --- |
| 71 | SCORPIUS | Revasc | --- | --- | --- | --- | --- | --- | 28 | 475 | --- | --- | 12 | 475 | --- | --- | --- | --- | --- | --- |
| 72 | SES SMART | Death | --- | --- | --- | --- | --- | --- | 2 | 85 | --- | --- | 0 | 86 | --- | --- | --- | --- | --- | --- |
| 72 | SES SMART | MI | --- | --- | --- | --- | --- | --- | 10 | 85 | --- | --- | 2 | 86 | --- | --- | --- | --- | --- | --- |
| 72 | SES SMART | Death or MI | --- | --- | --- | --- | --- | --- | 12 | 85 | --- | --- | 2 | 86 | --- | --- | --- | --- | --- | --- |
| 72 | SES SMART | Revasc | --- | --- | --- | --- | --- | --- | 27 | 85 | --- | --- | 9 | 86 | --- | --- | --- | --- | --- | --- |
| 73 | SIRIUS | Death | --- | --- | --- | --- | --- | --- | 44 | 2625 | --- | --- | 45 | 2665 | --- | --- | --- | --- | --- | --- |
| 73 | SIRIUS | MI | --- | --- | --- | --- | --- | --- | 34 | 2625 | --- | --- | 33 | 2665 | --- | --- | --- | --- | --- | --- |
| 73 | SIRIUS | Death or MI | --- | --- | --- | --- | --- | --- | 70 | 2625 | --- | --- | 74 | 2665 | --- | --- | --- | --- | --- | --- |
| 73 | SIRIUS | Revasc | --- | --- | --- | --- | --- | --- | 160 | 2625 | --- | --- | 88 | 2665 | --- | --- | --- | --- | --- | --- |
| 74 | SIRTAX | Death | --- | --- | --- | --- | --- | --- | --- | --- | 48 | 2545 | 55 | 2515 | --- | --- | --- | --- | --- | --- |
| 74 | SIRTAX | MI | --- | --- | --- | --- | --- | --- | --- | --- | 35 | 2545 | 33 | 2515 | --- | --- | --- | --- | --- | --- |
| 74 | SIRTAX | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 76 | 2545 | 85 | 2515 | --- | --- | --- | --- | --- | --- |
| 74 | SIRTAX | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 96 | 2545 | 78 | 2515 | --- | --- | --- | --- | --- | --- |
| 75 | SISA | Death | --- | --- | --- | --- | 1 | 91 | 0 | 85 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 75 | SISA | MI | --- | --- | --- | --- | 15 | 91 | 7 | 85 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 75 | SISA | Death or MI | --- | --- | --- | --- | 16 | 91 | 7 | 85 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 75 | SISA | Revasc | --- | --- | --- | --- | 37 | 91 | 30 | 85 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 76 | SORT OUT II | Death | --- | --- | --- | --- | --- | --- | --- | --- | 40 | 1550 | 41 | 1598 | --- | --- | --- | --- | --- | --- |
| 76 | SORT OUT II | MI | --- | --- | --- | --- | --- | --- | --- | --- | 53 | 1550 | 45 | 1598 | --- | --- | --- | --- | --- | --- |
| 76 | SORT OUT II | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 93 | 1550 | 86 | 1598 | --- | --- | --- | --- | --- | --- |
| 76 | SORT OUT II | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 81 | 1550 | 70 | 1598 | --- | --- | --- | --- | --- | --- |
| 77 | SORT OUT III | Death | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 69 | 3510 | 85 | 3486 | --- | --- | --- | --- |
| 77 | SORT OUT III | MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 37 | 3510 | 43 | 3486 | --- | --- | --- | --- |
| 77 | SORT OUT III | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 106 | 3510 | 128 | 3486 | --- | --- | --- | --- |
| 77 | SORT OUT III | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 76 | 3510 | 103 | 3486 | --- | --- | --- | --- |
| 78 | SORT-OUT IV | Death | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 66 | 2768 | --- | --- | --- | --- | 71 | 2780 |
| 78 | SORT-OUT IV | MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 31 | 2768 | --- | --- | --- | --- | 25 | 2780 |
| 78 | SORT-OUT IV | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 97 | 2768 | --- | --- | --- | --- | 96 | 2780 |
| 78 | SORT-OUT IV | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 86 | 2768 | --- | --- | --- | --- | 76 | 2780 |

| | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 88 | SoS | Death | --- | --- | 21 | 2425 | --- | --- | 39 | 2395 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 88 | SoS | MI | --- | --- | 41 | 1000 | --- | --- | 26 | 976 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 88 | SoS | Death or MI | --- | --- | 49 | 1000 | --- | --- | 46 | 976 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 88 | SoS | Revasc | --- | --- | 30 | 1000 | --- | --- | 101 | 976 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 79 | SPIRIT III | Death | --- | --- | --- | --- | --- | --- | --- | --- | 14 | 936 | --- | --- | --- | --- | --- | --- | 18 | 1908 |
| 79 | SPIRIT III | MI | --- | --- | --- | --- | --- | --- | --- | --- | 20 | 915 | --- | --- | --- | --- | --- | --- | 24 | 1887 |
| 79 | SPIRIT III | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 25 | 618 | --- | --- | --- | --- | --- | --- | 31 | 1284 |
| 79 | SPIRIT III | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 45 | 936 | --- | --- | --- | --- | --- | --- | 70 | 1908 |
| 80 | SPIRIT-II | Death | --- | --- | --- | --- | --- | --- | --- | --- | 10 | 385 | --- | --- | --- | --- | --- | --- | 13 | 1115 |
| 80 | SPIRIT-II | MI | --- | --- | --- | --- | --- | --- | --- | --- | 5 | 268 | --- | --- | --- | --- | --- | --- | 7 | 780 |
| 80 | SPIRIT-II | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 7 | 385 | --- | --- | --- | --- | --- | --- | 10 | 1115 |
| 81 | SPIRIT-IV | Death | --- | --- | --- | --- | --- | --- | --- | --- | 32 | 2458 | --- | --- | --- | --- | --- | --- | 49 | 4916 |
| 81 | SPIRIT-IV | MI | --- | --- | --- | --- | --- | --- | --- | --- | 47 | 2458 | --- | --- | --- | --- | --- | --- | 60 | 4916 |
| 81 | SPIRIT-IV | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 73 | 2458 | --- | --- | --- | --- | --- | --- | 108 | 4916 |
| 81 | SPIRIT-IV | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 106 | 2458 | --- | --- | --- | --- | --- | --- | 163 | 4916 |
| 82 | SPIRIT-V | Death | --- | --- | --- | --- | --- | --- | --- | --- | 3 | 104 | --- | --- | --- | --- | --- | --- | 3 | 215 |
| 82 | SPIRIT-V | MI | --- | --- | --- | --- | --- | --- | --- | --- | 9 | 104 | --- | --- | --- | --- | --- | --- | 7 | 215 |
| 82 | SPIRIT-V | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 12 | 104 | --- | --- | --- | --- | --- | --- | 10 | 215 |
| 82 | SPIRIT-V | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 6 | 104 | --- | --- | --- | --- | --- | --- | 21 | 215 |
| 83 | START | Death | --- | --- | --- | --- | 5 | 844 | 6 | 900 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 83 | START | MI | --- | --- | --- | --- | 6 | 844 | 5 | 900 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 83 | START | Death or MI | --- | --- | --- | --- | 11 | 844 | 11 | 900 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 83 | START | Revasc | --- | --- | --- | --- | 52 | 844 | 27 | 900 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 84 | STICH | Death | 244 | 2809 | 218 | 2847 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 84 | STICH | Revasc | 137 | 2809 | 27 | 2847 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 85 | STRESS | Death | --- | --- | --- | --- | 4 | 202 | 3 | 205 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 85 | STRESS | MI | --- | --- | --- | --- | 16 | 202 | 13 | 205 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 85 | STRESS | Death or MI | --- | --- | --- | --- | 20 | 202 | 16 | 205 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 85 | STRESS | Revasc | --- | --- | --- | --- | 35 | 202 | 24 | 205 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 86 | SWISSI-II | Death | 7 | 1071 | --- | --- | 4 | 979 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 86 | SWISSI-II | MI | 37 | 1071 | --- | --- | 10 | 979 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 86 | SWISSI-II | Death or MI | 44 | 1071 | --- | --- | 14 | 979 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 86 | SWISSI-II | Revasc | 23 | 1071 | --- | --- | 16 | 979 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87 | SYNTAX | Death | --- | --- | 102 | 4485 | --- | --- | --- | --- | 126 | 4515 | --- | --- | --- | --- | --- | --- | --- | --- |
| 87 | SYNTAX | MI | --- | --- | 34 | 4485 | --- | --- | --- | --- | 88 | 4515 | --- | --- | --- | --- | --- | --- | --- | --- |
| 87 | SYNTAX | Death or MI | --- | --- | 136 | 4485 | --- | --- | --- | --- | 214 | 4515 | --- | --- | --- | --- | --- | --- | --- | --- |
| 87 | SYNTAX | Revasc | --- | --- | 123 | 4485 | --- | --- | --- | --- | 234 | 4515 | --- | --- | --- | --- | --- | --- | --- | --- |
| 92 | TAXi | Death | --- | --- | --- | --- | --- | --- | --- | --- | 3 | 306 | 7 | 300 | --- | --- | --- | --- | --- | --- |
| 92 | TAXi | MI | --- | --- | --- | --- | --- | --- | --- | --- | 7 | 306 | 3 | 300 | --- | --- | --- | --- | --- | --- |
| 92 | TAXi | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 10 | 306 | 10 | 300 | --- | --- | --- | --- | --- | --- |
| 92 | TAXi | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 1 | 306 | 5 | 300 | --- | --- | --- | --- | --- | --- |
| 89 | TAXUS IV | Death | --- | --- | --- | --- | --- | --- | 72 | 3215 | 65 | 3255 | --- | --- | --- | --- | --- | --- | --- | --- |
| 89 | TAXUS IV | MI | --- | --- | --- | --- | --- | --- | 48 | 3215 | 47 | 3255 | --- | --- | --- | --- | --- | --- | --- | --- |
| 89 | TAXUS IV | Death or MI | --- | --- | --- | --- | --- | --- | 120 | 3215 | 112 | 3255 | --- | --- | --- | --- | --- | --- | --- | --- |
| 89 | TAXUS IV | Revasc | --- | --- | --- | --- | --- | --- | 176 | 3215 | 110 | 3255 | --- | --- | --- | --- | --- | --- | --- | --- |
| 90 | TAXUS-II | Death | --- | --- | --- | --- | --- | --- | 12 | 1350 | 9 | 655 | --- | --- | --- | --- | --- | --- | --- | --- |
| 90 | TAXUS-II | MI | --- | --- | --- | --- | --- | --- | 19 | 1350 | 6 | 655 | --- | --- | --- | --- | --- | --- | --- | --- |
| 90 | TAXUS-II | Death or MI | --- | --- | --- | --- | --- | --- | 31 | 1350 | 15 | 655 | --- | --- | --- | --- | --- | --- | --- | --- |
| 90 | TAXUS-II | Revasc | --- | --- | --- | --- | --- | --- | 60 | 1350 | 21 | 655 | --- | --- | --- | --- | --- | --- | --- | --- |
| 91 | TAXUS-V | Death | --- | --- | --- | --- | --- | --- | 8 | 425 | 7 | 420 | --- | --- | --- | --- | --- | --- | --- | --- |
| 91 | TAXUS-V | MI | --- | --- | --- | --- | --- | --- | 26 | 425 | 30 | 420 | --- | --- | --- | --- | --- | --- | --- | --- |
| 91 | TAXUS-V | Death or MI | --- | --- | --- | --- | --- | --- | 34 | 425 | 37 | 420 | --- | --- | --- | --- | --- | --- | --- | --- |
| 91 | TAXUS-V | Revasc | --- | --- | --- | --- | --- | --- | 98 | 425 | 68 | 420 | --- | --- | --- | --- | --- | --- | --- | --- |
| 95 | Thiele et al. (2005) | Death | --- | --- | 13 | 605 | --- | --- | 11 | 605 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 95 | Thiele et al. (2005) | MI | --- | --- | 7 | 605 | --- | --- | 5 | 605 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 95 | Thiele et al. (2005) | Death or MI | --- | --- | 20 | 605 | --- | --- | 16 | 605 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 95 | Thiele et al. (2005) | Revasc | --- | --- | 11 | 605 | --- | --- | 35 | 605 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 93 | TOSCA | Death | --- | --- | --- | --- | 1 | 208 | 3 | 202 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 93 | TOSCA | MI | --- | --- | --- | --- | 8 | 208 | 25 | 202 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 93 | TOSCA | Death or MI | --- | --- | --- | --- | 9 | 208 | 28 | 202 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 93 | TOSCA | Revasc | --- | --- | --- | --- | 63 | 208 | 43 | 202 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 94 | TWENTE | Death | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 15 | 695 | 14 | 692 |
| 94 | TWENTE | MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 32 | 695 | 32 | 692 |
| 94 | TWENTE | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 47 | 695 | 46 | 692 |
| 94 | TWENTE | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 23 | 695 | 19 | 692 |
| 96 | VA | Death | 78 | 1770 | 56 | 1660 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96 | VA | MI | 85 | 1770 | 80 | 1660 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 96 | VA | Death or MI | 163 | 1770 | 136 | 1660 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 96 | VA | Revasc | 89 | 1770 | 9 | 1560 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 97 | VA-ACME | Death | 7 | 321 | --- | --- | 5 | 315 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 97 | VA-ACME | MI | 7 | 321 | --- | --- | 10 | 315 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 97 | VA-ACME | Death or MI | 13 | 321 | --- | --- | 12 | 315 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 97 | VA-ACME | Revasc | 46 | 321 | --- | --- | 44 | 315 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 98 | WIDEST | Death | --- | --- | --- | --- | 3 | 146 | 0 | 154 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 98 | WIDEST | MI | --- | --- | --- | --- | 5 | 146 | 6 | 154 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 98 | WIDEST | Death or MI | --- | --- | --- | --- | 7 | 146 | 6 | 154 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 98 | WIDEST | Revasc | --- | --- | --- | --- | 25 | 146 | 28 | 154 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 99 | ZEST | Death | --- | --- | --- | --- | --- | --- | --- | --- | 10 | 884 | 7 | 878 | 6 | 883 | --- | --- | --- | --- |
| 99 | ZEST | MI | --- | --- | --- | --- | --- | --- | --- | --- | 62 | 884 | 55 | 878 | 47 | 883 | --- | --- | --- | --- |
| 99 | ZEST | Death or MI | --- | --- | --- | --- | --- | --- | --- | --- | 67 | 884 | 61 | 878 | 51 | 883 | --- | --- | --- | --- |
| 99 | ZEST | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 67 | 884 | 16 | 878 | 46 | 883 | --- | --- | --- | --- |
| 100 | Zhang et al (2006) | MI | --- | --- | --- | --- | --- | --- | --- | --- | 9 | 187 | 7 | 225 | --- | --- | --- | --- | --- | --- |
| 100 | Zhang et al (2006) | Revasc | --- | --- | --- | --- | --- | --- | --- | --- | 16 | 187 | 14 | 225 | --- | --- | --- | --- | --- | --- |

CABG=Coronary artery bypass graft surgery; PTCA=Percutaneous transluminal coronary angioplasty; BMS=Bare metal stent; DES=Drug eluting stent; PES=Paclitaxel eluting stent; SES=Sirolimus eluting stent; R-ZES=Zotarolimus eluting Resolute stent; E-ZES=Zotarolimus eluting Endeavor Stent; EES=Everolimus eluting stent
MI=Myocardial infarction; Death=All-cause death, Revasc=Repeat revascularisation; Death or MI=All-cause death or myocardial infarction

**Supplemental Table 3** **Number of trials, patients and patient-years by intervention**

| Clinical Endpoints | Intervention | Nr. of Trials | Randomised patients | Follow-Up (patient-years) |
|---|---|---|---|---|
| **ALL-CAUSE DEATH** | | | | |
| | Medical therapy | 14 | 6,846 | 30,628 |
| | CABG | 22 | 8,920 | 38,709 |
| | PTCA | 25 | 6,920 | 17,678 |
| | BMS | 44 | 15,787 | 45,467 |
| | PES | 25 | 11,195 | 27,592 |
| | SES | 37 | 19,391 | 45,879 |
| | E-ZES | 8 | 8,937 | 27,134 |
| | R-ZES | 4 | 2,285 | 3,384 |
| | EES | 17 | 13,272 | 23,619 |
| **MYOCARDIAL INFARCTION** | | | | |
| | Medical therapy | 12 | 5,645 | 25,148 |
| | CABG | 18 | 7,293 | 29,691 |
| | PTCA | 27 | 7,151 | 19,009 |
| | BMS | 42 | 15,104 | 41,908 |
| | PES | 26 | 11,398 | 27,641 |
| | SES | 37 | 19,387 | 45,854 |
| | E-ZES | 8 | 8,937 | 27,134 |
| | R-ZES | 4 | 2,285 | 3,384 |
| | EES | 17 | 13,272 | 23,263 |
| **DEATH OR MYOCARDIAL INFARCTION** | | | | |
| | Medical therapy | 11 | 5,481 | 23,874 |
| | CABG | 18 | 7,293 | 29,691 |
| | PTCA | 24 | 6,720 | 17,561 |
| | BMS | 41 | 15,099 | 41,469 |
| | PES | 24 | 11,118 | 24,777 |
| | SES | 37 | 19,391 | 45,879 |
| | E-ZES | 8 | 8,937 | 24,515 |
| | R-ZES | 4 | 2,285 | 3,384 |
| | EES | 16 | 13,049 | 21,880 |
| **REPEAT REVASCULARISATION** | | | | |
| | Medical therapy | 13 | 6,247 | 26,927 |
| | CABG | 20 | 8,135 | 28,664 |
| | PTCA | 28 | 7,351 | 18,108 |
| | BMS | 44 | 15,275 | 41,303 |
| | PES | 25 | 10,856 | 27,926 |
| | SES | 37 | 19,266 | 41,516 |
| | E-ZES | 6 | 8,096 | 25,720 |
| | R-ZES | 4 | 2,285 | 3,134 |
| | EES | 16 | 12,771 | 24,106 |

CABG=Coronary artery bypass graft surgery; PTCA=Percutaneous transluminal coronary angioplasty; BMS=Bare metal stent; DES=Drug eluting stent; PES=Paclitaxel eluting stent; SES=Sirolimus eluting stent; R-ZES=Zorarolimus eluting Resolute stent; E-ZES=Zotarolimus eluting Endeavor Stent; EES=Everolimus eluting stent

| **Supplemental Table 4** | **Ranking of interventions** | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | All-Cause Mortality | | Myocardial Infarction | | Death or Myocardial Infarction | | Subsequent Revascularisation | |
| Intervention | Probability to be better than MT | Estimated rank (95%CI) | Probability to be better than MT | Estimated rank (95%CrI) | Probability to be better than MT | Estimated rank (95%CI) | Probability to be better than MT | Estimated rank (95%CI) |
| CABG | 100 | 3 (1 to 6) | 97.9 | 3 (1 to 6) | 99.6 | 3 (1 to 5) | 100.0 | 1 (1 to 1) |
| EES | 99.1 | 2 (1 to 5) | 97.2 | 2 (1 to 5) | 99.0 | 2 (1 to 5) | 100.0 | 3 (2 to 4) |
| R-ZES | 97.5 | 1 (1 to 8) | 81.7 | 3 (1 to 9) | 91.2 | 3 (1 to 8) | 100.0 | 2 (2 to 5) |
| PTCA | 94.2 | 4 (1 to 9) | 86.7 | 5 (1 to 8) | 99.0 | 3 (1 to 6) | 62.4 | 8 (8 to 9) |
| BMS | 87.6 | 7 (4 to 9) | 35.8 | 8 (5 to 9) | 57.6 | 7 (5 to 9) | 100.0 | 7 (7 to 7) |
| E-ZES | 86.7 | 5 (2 to 9) | 91.3 | 3 (1 to 7) | 92.9 | 4 (1 to 7) | 100.0 | 5 (4 to 6) |
| SES | 82.2 | 6 (3 to 9) | 68.3 | 6 (3 to 8) | 68.3 | 6 (4 to 8) | 100.0 | 4 (2 to 4) |
| PES | 79.2 | 7 (3 to 9) | 12.7 | 9 (7 to 9) | 26.9 | 9 (6 to 9) | 100.0 | 6 (5 to 6) |
| MT | 50.0* (reference) | 9 (5 to 9) | 50.0* (reference) | 7 (3 to 9) | 50.0* (reference) | 8 (5 to 9) | 50.0* (reference) | 9 (8 to 9) |

MT: medical therapy; CABG: coronary artery bypass graft; PTCA: percutaneous transluminal coronary angioplasty; BMS: bare metal stents; PES: paclitaxel eluting stent; SES: sirolimus eluting stent; E-ZES: zotarolimus eluting (Endeavor) stent; R-ZES: zotarolimus eluting (Resolute) stent; EES: everolimus eluting stent. RR: Rate ratio; CI: credibility interval.

*A probability of 50% is the reference (medical therapy).

**Supplemental Table 5** **Ranking of interventions in trials initiated 1999 or later**

| | All-Cause Mortality | | Myocardial Infarction | | Death or Myocardial Infarction | | Subsequent Revascularisation | |
|---|---|---|---|---|---|---|---|---|
| Intervention | Probability to be better than MT | Estimated rank (95%CI) | Probability to be better than MT | Estimated rank (95%CI) | Probability to be better than MT | Estimated rank (95%CI) | Probability to be better than MT | Estimated rank (95%CI) |
| CABG | 97.7 | 3 (1 to 6) | 100.0 | 1 (1 to 1) | 100.0 | 1 (1 to 2) | 100.0 | 1 (1 to 1) |
| EES | 95.9 | 2 (1 to 4) | 99.2 | 2 (2 to 4) | 99.0 | 3 (2 to 4) | 100.0 | 3 (2 to 4) |
| R-ZES | 92.8 | 1 (1 to 8) | 91.3 | 3 (2 to 6) | 92.4 | 3 (1 to 6) | 100.0 | 2 (2 to 5) |
| E-ZES | 65.7 | 5 (2 to 8) | 91.5 | 4 (2 to 6) | 89.0 | 4 (2 to 6) | 100.0 | 5 (4 to 6) |
| SES | 52.4 | 6 (3 to 8) | 82.1 | 5 (3 to 6) | 65.1 | 5 (4 to 7) | 100.0 | 4 (2 to 4) |
| MT | 50.0* (reference) | 6 (3 to 8) | 50.0* (reference) | 6 (3 to 7) | 50.0* (reference) | 6 (3 to 8) | 50.0* (reference) | 8 (8 to 8) |
| PES | 47.6 | 6 (3 to 8) | 11.3 | 7 (6 to 8) | 21.3 | 7 (6 to 8) | 100.0 | 6 (5 to 6) |
| BMS | 40.9 | 7 (3 to 8) | 2.3 | 8 (7 to 8) | 8.8 | 8 (6 to 8) | 99.9 | 7 (7 to 7) |

MT: medical therapy; CABG: coronary artery bypass graft; PTCA: percutaneous transluminal coronary angioplasty; BMS: bare metal stents; PES: paclitaxel eluting stent; SES: sirolimus eluting stent; E-ZES: zotarolimus eluting (Endeavor) stent; R-ZES: zotarolimus eluting (Resolute) stent; EES: everolimus eluting stent. RR: Rate ratio; CI: credibility interval.

*A probability of 50% is the reference (medical therapy).

| Supplemental Table 6 | Estimated rate ratios for all possible comparisons | | | | | | | |
|---|---|---|---|---|---|---|---|---|

**ALL-CAUSE MORTALITY**

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **MT** | 0.77 (0.58 to 0.99) | 0.66 (0.25 to 1.60) | 0.98 (0.74 to 1.26) | - | - | - | - | 0.33 (0.03 to 3.16) |
| 0.80 (0.70 to 0.91) | **CABG** | 1.03 (0.55 to 1.65) | 1.00 (0.56 to 1.46) | 1.23 (0.95 to 1.59) | 1.02 (0.31 to 2.16) | - | - | - |
| 0.85 (0.68 to 1.04) | 1.06 (0.88 to 1.27) | **PTCA** | 0.94 (0.62 to 1.64) | - | - | - | - | - |
| 0.92 (0.79 to 1.05) | 1.15 (1.01 to 1.31) | 1.08 (0.89 to 1.33) | **BMS** | 0.98 (0.65 to 1.48) | 1.05 (0.74 to 1.50) | 0.81 (0.21 to 2.78) | - | 0.73 (0.18 to 2.73) |
| 0.92 (0.75 to 1.12) | 1.15 (0.96 to 1.38) | 1.08 (0.86 to 1.39) | 1.00 (0.85 to 1.18) | **PES** | 1.01 (0.75 to 1.36) | 0.85 (0.30 to 2.24) | 1.02 (0.14 to 7.21) | 0.74 (0.48 to 1.06) |
| 0.91 (0.75 to 1.10) | 1.14 (0.96 to 1.35) | 1.08 (0.86 to 1.36) | 1.00 (0.85 to 1.16) | 0.99 (0.86 to 1.15) | **SES** | 0.96 (0.49 to 1.55) | 0.50 (0.09 to 2.73) | 0.87 (0.57 to 1.16) |
| 0.88 (0.69 to 1.10) | 1.10 (0.89 to 1.35) | 1.03 (0.80 to 1.34) | 0.95 (0.78 to 1.16) | 0.95 (0.79 to 1.15) | 0.96 (0.82 to 1.12) | **E-ZES** | - | - |
| 0.65 (0.42 to 1.00) | 0.81 (0.53 to 1.24) | 0.77 (0.49 to 1.20) | 0.71 (0.47 to 1.08) | 0.71 (0.47 to 1.06) | 0.71 (0.47 to 1.06) | 0.74 (0.48 to 1.13) | **R-ZES** | 1.12 (0.26 to 4.71) |
| 0.75 (0.59 to 0.96) | 0.94 (0.76 to 1.17) | 0.88 (0.68 to 1.17) | 0.82 (0.67 to 1.00) | 0.82 (0.68 to 0.98) | 0.82 (0.70 to 0.98) | 0.86 (0.69 to 1.06) | 1.15 (0.79 to 1.67) | **EES** |

Estimates of rate ratios for all possible comparisons from conventional meta-analysis of direct randomised comparisons (top right) and network meta-analysis (bottom left)

- indicates that no direct comparison is available

**MYOCARDIAL INFARCTION**

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **MT** | 0.69 (0.24 to 1.87) | 0.87 (0.34 to 2.38) | 1.07 (0.66 to 1.46) | - | - | - | - | 1.06 (0.51 to 2.19) |
| 0.79 (0.63 to 0.99) | **CABG** | 0.99 (0.54 to 1.75) | 0.89 (0.46 to 1.51) | 2.57 (1.73 to 3.82) | 1.84 (0.83 to 3.79) | - | - | - |
| 0.88 (0.70 to 1.11) | 1.12 (0.91 to 1.38) | **PTCA** | 1.06 (0.75 to 1.49) | - | - | - | - | - |
| 1.04 (0.84 to 1.27) | 1.32 (1.08 to 1.60) | 1.18 (0.96 to 1.44) | **BMS** | 0.84 (0.47 to 1.22) | 0.71 (0.39 to 1.19) | 0.65 (0.16 to 2.57) | - | 0.50 (0.11 to 2.26) |
| 1.18 (0.88 to 1.54) | 1.50 (1.15 to 1.90) | 1.34 (1.00 to 1.74) | 1.13 (0.91 to 1.40) | **PES** | 0.88 (0.72 to 1.08) | 0.63 (0.21 to 1.62) | 0.89 (0.32 to 2.45) | 0.53 (0.40 to 0.74) |
| 0.94 (0.71 to 1.22) | 1.20 (0.93 to 1.51) | 1.07 (0.81 to 1.38) | 0.90 (0.74 to 1.10) | 0.80 (0.67 to 0.95) | **SES** | 0.92 (0.45 to 1.30) | 0.85 (0.52 to 1.40) | 0.93 (0.66 to 1.30) |
| 0.80 (0.56 to 1.10) | 1.02 (0.73 to 1.38) | 0.91 (0.64 to 1.25) | 0.77 (0.58 to 1.01) | 0.68 (0.52 to 0.87) | 0.85 (0.67 to 1.07) | **EZES** | - | - |
| 0.82 (0.52 to 1.26) | 1.04 (0.67 to 1.58) | 0.93 (0.59 to 1.44) | 0.79 (0.52 to 1.18) | 0.70 (0.47 to 1.02) | 0.87 (0.60 to 1.27) | 1.02 (0.67 to 1.58) | **RZES** | 0.92 (0.24 to 3.75) |
| 0.75 (0.55 to 1.01) | 0.96 (0.71 to 1.26) | 0.85 (0.62 to 1.15) | 0.72 (0.56 to 0.93) | 0.64 (0.51 to 0.79) | 0.80 (0.65 to 0.99) | 0.94 (0.70 to 1.27) | 0.92 (0.64 to 1.31) | **EES** |

Estimates of rate ratios for all possible comparisons from conventional meta-analysis of direct randomised comparisons (top right) and network meta-analysis (bottom left)

- indicates that no direct comparison is available

**DEATH OR MYOCARDIAL INFARCTION**

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **MT** | 0.76 (0.35 to 1.62) | 0.69 (0.26 to 1.78) | 1.04 (0.72 to 1.31) | - | - | - | - | 0.87 (0.43 to 1.74) |
| 0.81 (0.70 to 0.94) | **CABG** | 1.00 (0.57 to 1.53) | 0.93 (0.57 to 1.33) | 1.56 (1.26 to 1.94) | 1.34 (0.53 to 2.40) | - | - | - |
| 0.83 (0.70 to 0.97) | 1.02 (0.88 to 1.17) | **PTCA** | 1.10 (0.81 to 1.58) | - | - | - | - | - |
| 0.99 (0.85 to 1.12) | 1.22 (1.05 to 1.38) | 1.19 (1.02 to 1.37) | **BMS** | 0.91 (0.63 to 1.21) | 0.89 (0.64 to 1.22) | 0.78 (0.21 to 3.01) | - | 0.65 (0.18 to 2.48) |
| 1.06 (0.87 to 1.27) | 1.31 (1.09 to 1.53) | 1.28 (1.05 to 1.54) | 1.07 (0.93 to 1.24) | **PES** | 0.94 (0.80 to 1.11) | 0.75 (0.39 to 1.38) | 0.91 (0.37 to 2.25) | 0.66 (0.47 to 0.86) |
| 0.96 (0.79 to 1.13) | 1.18 (1.00 to 1.37) | 1.16 (0.96 to 1.37) | 0.97 (0.85 to 1.10) | 0.90 (0.80 to 1.02) | **SES** | 0.85 (0.44 to 1.41) | 0.89 (0.55 to 1.44) | 0.90 (0.72 to 1.12) |
| 0.85 (0.67 to 1.05) | 1.05 (0.83 to 1.28) | 1.03 (0.81 to 1.27) | 0.86 (0.71 to 1.03) | 0.80 (0.67 to 0.95) | 0.89 (0.76 to 1.03) | **EZES** | - | - |
| 0.81 (0.59 to 1.10) | 1.00 (0.73 to 1.34) | 0.97 (0.71 to 1.34) | 0.82 (0.62 to 1.10) | 0.76 (0.58 to 1.01) | 0.84 (0.64 to 1.11) | 0.95 (0.70 to 1.30) | **RZES** | 0.99 (0.27 to 3.34) |
| 0.78 (0.63 to 0.96) | 0.96 (0.79 to 1.17) | 0.94 (0.76 to 1.17) | 0.79 (0.67 to 0.94) | 0.74 (0.64 to 0.86) | 0.82 (0.71 to 0.94) | 0.92 (0.76 to 1.13) | 0.97 (0.75 to 1.25) | **EES** |

Estimates of rate ratios for all possible comparisons from conventional meta-analysis of direct randomised comparisons (top right) and network meta-analysis (bottom left)

- indicates that no direct comparison is available

**SUBSEQUENT REVASCULARISATION**

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| **MT** | 0.17 (0.09 to 0.28) | 0.88 (0.63 to 1.22) | 0.76 (0.51 to 1.22) | - | - | - | - | 0.16 (0.09 to 0.28) |
| 0.16 (0.13 to 0.20) | **CABG** | 6.19 (3.50 to 11.38) | 3.93 (2.88 to 5.79) | 1.89 (1.52 to 2.35) | 2.93 (1.46 to 6.60) | - | - | - |
| 0.97 (0.82 to 1.16) | 5.96 (5.05 to 7.11) | **PTCA** | 0.70 (0.60 to 0.80) | - | - | - | - | - |
| 0.69 (0.59 to 0.82) | 4.25 (3.64 to 5.02) | 0.71 (0.63 to 0.81) | **BMS** | 0.68 (0.54 to 0.90) | 0.38 (0.29 to 0.49) | 0.53 (0.39 to 0.73) | - | 0.36 (0.24 to 0.56) |
| 0.44 (0.35 to 0.55) | 2.68 (2.19 to 3.32) | 0.45 (0.37 to 0.55) | 0.63 (0.53 to 0.75) | **PES** | 0.60 (0.38 to 0.89) | 0.77 (0.17 to 3.08) | 0.23 (0.08 to 0.67) | 0.71 (0.36 to 1.37) |
| 0.29 (0.24 to 0.36) | 1.80 (1.49 to 2.19) | 0.30 (0.25 to 0.37) | 0.42 (0.36 to 0.50) | 0.67 (0.57 to 0.78) | **SES** | 1.48 (0.77 to 3.30) | 0.83 (0.25 to 2.73) | 0.93 (0.73 to 1.18) |
| 0.38 (0.29 to 0.51) | 2.33 (1.79 to 3.08) | 0.39 (0.30 to 0.51) | 0.55 (0.43 to 0.70) | 0.87 (0.69 to 1.10) | 1.29 (1.04 to 1.62) | **EZES** | - | - |
| 0.26 (0.17 to 0.40) | 1.61 (1.05 to 2.45) | 0.27 (0.17 to 0.41) | 0.38 (0.25 to 0.56) | 0.60 (0.40 to 0.88) | 0.89 (0.60 to 1.32) | 0.69 (0.44 to 1.06) | **RZES** | 0.89 (0.24 to 3.12) |
| 0.27 (0.21 to 0.35) | 1.65 (1.29 to 2.11) | 0.28 (0.22 to 0.35) | 0.39 (0.31 to 0.48) | 0.61 (0.51 to 0.74) | 0.91 (0.76 to 1.10) | 0.71 (0.54 to 0.92) | 1.02 (0.72 to 1.49) | **EES** |

Estimates of rate ratios for all possible comparisons from conventional meta-analysis of direct randomised comparisons (top right) and network meta-analysis (bottom left)

- indicates that no direct comparison is available

## Supplemental Figure 2 – Comparison adjusted funnel plots




Comparison-adjusted funnel plots to investigate the presence of small-study effects in the network meta-analysis.[101] . Estimates below one indicate that the benefit of the experimental intervention is more pronounced in the trial than the pooled estimate. Observations from small studies missing on the right side of the line of null effect (ratio of rate ratios > 1) indicate that small studies tend to exaggerate the effectiveness of experimental treatments.

| Supplemental Table 7 | Sensitivity analysis for different priors for $\tau$ and frequentist meta-analysis | | | | | |
|---|---|---|---|---|---|---|
| | **Main Analysis** | **Exponential distribution** | **Uniform distribution** | **Half-normal distribution** | **Frequentist meta analysis using Rate Ratios** | **Frequentist meta analysis using Risk Ratios** |
| **ALL-CAUSE MORTALITY** | | | | | | |
| CABG versus Medical Therapy | 0.80 (0.70 to 0.91) | 0.80 (0.71 to 0.90) | 0.80 (0.71 to 0.90) | 0.80 (0.71 to 0.90) | 0.81 (0.73 to 0.90) | 0.81 (0.73 to 0.91) |
| PTCA versus Medical Therapy | 0.85 (0.68 to 1.04) | 0.85 (0.71 to 1.03) | 0.85 (0.70 to 1.02) | 0.86 (0.68 to 1.04) | 0.88 (0.73 to 1.05) | 0.88 (0.72 to 1.06) |
| BMS versus Medical Therapy | 0.92 (0.79 to 1.05) | 0.93 (0.80 to 1.06) | 0.92 (0.80 to 1.06) | 0.91 (0.79 to 1.05) | 0.94 (0.83 to 1.06) | 0.94 (0.82 to 1.07) |
| **EARLY GENERATION DES** | | | | | | |
| PES versus Medical Therapy | 0.92 (0.75 to 1.12) | 0.92 (0.77 to 1.09) | 0.93 (0.77 to 1.10) | 0.93 (0.76 to 1.09) | 0.95 (0.80 to 1.12) | 0.95 (0.79 to 1.14) |
| SES versus Medical Therapy | 0.91 (0.75 to 1.10) | 0.92 (0.76 to 1.08) | 0.92 (0.77 to 1.08) | 0.92 (0.76 to 1.10) | 0.93 (0.79 to 1.10) | 0.94 (0.78 to 1.12) |
| E-ZES versus Medical Therapy | 0.88 (0.69 to 1.10) | 0.89 (0.71 to 1.08) | 0.88 (0.70 to 1.09) | 0.88 (0.70 to 1.10) | 0.91 (0.74 to 1.10) | 0.91 (0.73 to 1.12) |
| **NEW GENERATION DES** | | | | | | |
| R-ZES versus Medical Therapy | 0.65 (0.42 to 1.00) | 0.65 (0.43 to 1.00) | 0.65 (0.43 to 0.97) | 0.64 (0.43 to 0.97) | 0.67 (0.44 to 1.02) | 0.67 (0.44 to 1.02) |
| EES versus Medical Therapy | 0.75 (0.59 to 0.96) | 0.76 (0.60 to 0.95) | 0.76 (0.61 to 0.93) | 0.76 (0.61 to 0.93) | 0.78 (0.63 to 0.96) | 0.78 (0.62 to 0.97) |

CABG=Coronary artery bypass graft surgery; PTCA=Percutaneous transluminal coronary angioplasty; BMS=Bare metal stent; DES=Drug eluting stent;
PES=Paclitaxel eluting stent; SES=Sirolimus eluting stent; R-ZES=Zotarolimus eluting Resolute stent; E-ZES=Zotarolimus eluting Endeavor Stent; EES=Everolimus eluting stent

| | Main Analysis | Exponential distribution | Uniform distribution | Half-normal distribution | Frequentist meta-analysis using Rate Ratios | Frequentist meta-analysis using Risk Ratios |
|---|---|---|---|---|---|---|
| **MYOCARDIAL INFARCTION** | | | | | | |
| CABG versus Medical Therapy | 0.79 (0.63 to 0.99) | 0.79 (0.62 to 1.00) | 0.78 (0.62 to 0.99) | 0.79 (0.62 to 1.00) | 0.79 (0.64 to 0.99) | 0.79 (0.63 to 0.99) |
| PTCA versus Medical Therapy | 0.88 (0.70 to 1.11) | 0.88 (0.69 to 1.12) | 0.88 (0.69 to 1.11) | 0.88 (0.69 to 1.13) | 0.90 (0.72 to 1.13) | 0.89 (0.71 to 1.12) |
| BMS versus Medical Therapy | 1.04 (0.84 to 1.27) | 1.04 (0.83 to 1.29) | 1.03 (0.83 to 1.28) | 1.04 (0.83 to 1.28) | 1.04 (0.85 to 1.28) | 1.03 (0.84 to 1.27) |
| **EARLY GENERATION DES** | | | | | | |
| PES versus Medical Therapy | 1.18 (0.88 to 1.54) | 1.18 (0.86 to 1.56) | 1.16 (0.85 to 1.53) | 1.17 (0.87 to 1.55) | 1.20 (0.91 to 1.57) | 1.18 (0.89 to 1.56) |
| SES versus Medical Therapy | 0.94 (0.71 to 1.22) | 0.94 (0.70 to 1.23) | 0.93 (0.69 to 1.22) | 0.94 (0.71 to 1.22) | 0.96 (0.74 to 1.25) | 0.95 (0.72 to 1.24) |
| E-ZES versus Medical Therapy | 0.80 (0.56 to 1.10) | 0.80 (0.55 to 1.11) | 0.79 (0.54 to 1.09) | 0.80 (0.55 to 1.11) | 0.82 (0.59 to 1.14) | 0.80 (0.57 to 1.12) |
| **NEW GENERATION DES** | | | | | | |
| R-ZES versus Medical Therapy | 0.82 (0.52 to 1.26) | 0.82 (0.52 to 1.27) | 0.81 (0.51 to 1.26) | 0.82 (0.52 to 1.28) | 0.83 (0.55 to 1.27) | 0.82 (0.53 to 1.27) |
| EES versus Medical Therapy | 0.75 (0.55 to 1.01) | 0.75 (0.54 to 1.02) | 0.74 (0.53 to 1.01) | 0.75 (0.54 to 1.01) | 0.76 (0.57 to 1.03) | 0.75 (0.56 to 1.02) |

CABG=Coronary artery bypass graft surgery; PTCA=Percutaneous transluminal coronary angioplasty; BMS=Bare metal stent; DES=Drug eluting stent;
PES=Paclitaxel eluting stent; SES=Sirolimus eluting stent; R-ZES=Zotarolimus eluting Resolute stent; E-ZES=Zotarolimus eluting Endeavor Stent; EES=Everolimus eluting stent

| | Main Analysis | Exponential distribution | Uniform distribution | Half-normal distribution | Frequentist meta-analysis using Rate Ratios | Frequentist meta-analysis using Risk Ratios |
|---|---|---|---|---|---|---|
| **DEATH OR MYOCARDIAL INFARCTION** | | | | | | |
| CABG versus Medical Therapy | 0.81 (0.70 to 0.94) | 0.82 (0.70 to 0.95) | 0.81 (0.70 to 0.95) | 0.81 (0.69 to 0.95) | 0.82 (0.71 to 0.94) | 0.81 (0.70 to 0.94) |
| PTCA versus Medical Therapy | 0.83 (0.70 to 0.97) | 0.83 (0.70 to 0.98) | 0.83 (0.69 to 0.98) | 0.83 (0.69 to 0.98) | 0.84 (0.72 to 1.00) | 0.83 (0.70 to 0.98) |
| BMS versus Medical Therapy | 0.99 (0.85 to 1.12) | 0.99 (0.85 to 1.13) | 0.99 (0.84 to 1.13) | 0.98 (0.84 to 1.13) | 0.99 (0.86 to 1.14) | 0.97 (0.84 to 1.12) |
| **EARLY GENERATION DES** | | | | | | |
| PES versus Medical Therapy | 1.06 (0.87 to 1.27) | 1.07 (0.87 to 1.28) | 1.06 (0.86 to 1.26) | 1.05 (0.86 to 1.28) | 1.07 (0.89 to 1.29) | 1.05 (0.87 to 1.27) |
| SES versus Medical Therapy | 0.96 (0.79 to 1.13) | 0.97 (0.79 to 1.14) | 0.96 (0.78 to 1.14) | 0.95 (0.78 to 1.14) | 0.97 (0.81 to 1.16) | 0.95 (0.79 to 1.14) |
| E-ZES versus Medical Therapy | 0.85 (0.67 to 1.05) | 0.86 (0.66 to 1.06) | 0.85 (0.66 to 1.06) | 0.84 (0.65 to 1.05) | 0.86 (0.69 to 1.08) | 0.83 (0.66 to 1.05) |
| **NEW GENERATION DES** | | | | | | |
| R-ZES versus Medical Therapy | 0.81 (0.59 to 1.10) | 0.82 (0.58 to 1.11) | 0.81 (0.58 to 1.11) | 0.80 (0.56 to 1.10) | 0.82 (0.60 to 1.11) | 0.80 (0.58 to 1.10) |
| EES versus Medical Therapy | 0.78 (0.63 to 0.96) | 0.79 (0.63 to 0.97) | 0.78 (0.62 to 0.96) | 0.78 (0.62 to 0.96) | 0.79 (0.65 to 0.98) | 0.78 (0.63 to 0.96) |

CABG=Coronary artery bypass graft surgery; PTCA=Percutaneous transluminal coronary angioplasty; BMS=Bare metal stent; DES=Drug eluting stent;
PES=Paclitaxel eluting stent; SES=Sirolimus eluting stent; R-ZES=Zotarolimus eluting Resolute stent; E-ZES=Zotarolimus eluting Endeavor Stent; EES=Everolimus eluting stent

| | Main Analysis | Exponential distribution | Uniform distribution | Half-normal distribution | Frequentist meta-analysis using Rate Ratios | Frequentist meta-analysis using Risk Ratios |
|---|---|---|---|---|---|---|
| **SUBSEQUENT REVASCULARISATION** | | | | | | |
| CABG versus Medical Therapy | 0.16 (0.13 to 0.20) | 0.16 (0.13 to 0.20) | 0.16 (0.13 to 0.20) | 0.16 (0.13 to 0.20) | 0.17 (0.14 to 0.20) | 0.17 (0.14 to 0.20) |
| PTCA versus Medical Therapy | 0.97 (0.82 to 1.16) | 0.97 (0.82 to 1.16) | 0.98 (0.82 to 1.17) | 0.97 (0.82 to 1.16) | 0.97 (0.82 to 1.14) | 0.97 (0.83 to 1.14) |
| BMS versus Medical Therapy | 0.69 (0.59 to 0.82) | 0.69 (0.59 to 0.82) | 0.69 (0.59 to 0.82) | 0.69 (0.59 to 0.81) | 0.69 (0.60 to 0.80) | 0.69 (0.59 to 0.80) |
| **EARLY GENERATION DES** | | | | | | |
| PES versus Medical Therapy | 0.44 (0.35 to 0.55) | 0.44 (0.35 to 0.55) | 0.44 (0.35 to 0.55) | 0.44 (0.35 to 0.55) | 0.43 (0.35 to 0.53) | 0.43 (0.35 to 0.54) |
| SES versus Medical Therapy | 0.29 (0.24 to 0.36) | 0.29 (0.24 to 0.36) | 0.29 (0.24 to 0.36) | 0.29 (0.23 to 0.36) | 0.30 (0.24 to 0.36) | 0.30 (0.24 to 0.36) |
| E-ZES versus Medical Therapy | 0.38 (0.29 to 0.51) | 0.38 (0.29 to 0.51) | 0.38 (0.29 to 0.51) | 0.38 (0.28 to 0.51) | 0.38 (0.29 to 0.49) | 0.38 (0.29 to 0.49) |
| **NEW GENERATION DES** | | | | | | |
| R-ZES versus Medical Therapy | 0.26 (0.17 to 0.40) | 0.26 (0.17 to 0.40) | 0.26 (0.17 to 0.41) | 0.26 (0.17 to 0.40) | 0.27 (0.18 to 0.41) | 0.27 (0.18 to 0.41) |
| EES versus Medical Therapy | 0.27 (0.21 to 0.35) | 0.27 (0.21 to 0.35) | 0.27 (0.21 to 0.35) | 0.27 (0.21 to 0.34) | 0.27 (0.21 to 0.34) | 0.27 (0.21 to 0.34) |

CABG=Coronary artery bypass graft surgery; PTCA=Percutaneous transluminal coronary angioplasty; BMS=Bare metal stent; DES=Drug eluting stent;
PES=Paclitaxel eluting stent; SES=Sirolimus eluting stent; R-ZES=Zotarolimus eluting Resolute stent; E-ZES=Zotarolimus eluting Endeavor Stent; EES=Everolimus eluting stent

| **Supplemental Table 8** | **Assessment of model fit** | | | |
|---|---|---|---|---|
| **Outcome** | **Data points** | **Residual deviance** | **Residuals** | **Q-Q plots** |
| | | **Mean** | **Number (%) within 1·96 SND** | |
| **All trials** | | | | |
| All-cause mortality | 196 | 204 | 194 (99.0%) | Adequate |
| Myocardial infarction | 192 | 198 | 192 (100%) | Adequate |
| Death or myocardial infarction | 184 | 205 | 183 (99.5%) | Adequate |
| Subsequent revascularisation | 194 | 214 | 193 (99.5%) | Adequate |
| **Contemporary trials initiated 1999 or later** | | | | |
| All-cause mortality | 125 | 117 | 123 (98.4%) | Adequate |
| Myocardial infarction | 123 | 114 | 122 (99.2%) | Adequate |
| Death or myocardial infarction | 121 | 119 | 120 (99.2%) | Adequate |
| Subsequent revascularisation | 121 | 142 | 120 (99.2%) | Adequate |

SND: Standard normal distribution

The model was considered to provide an adequate fit to the data, if (1) the mean of the residual deviance was similar to the number of data points used in the model, (2) at least 95% of means of standardised node-based residuals were within 1.96 of the standard normal distribution, and (3) Q-Q plots of residuals were lying closely around a line on visual inspection.

| **Supplemental Table 9** | **Estimates of between trial heterogeneity** |
|---|---|
| | $\tau^2$ (95% CI) |
| **All trials** | |
| All-cause mortality | 0.005 (0.000 to 0.026) |
| Myocardial infarction | 0.047 (0.011 to 0.107) |
| Death or myocardial infarction | 0.014 (0.001 to 0.044) |
| Subsequent revascularisation | 0.043 (0.017 to 0.085) |
| **Contemporary trials initiated 1999 or later** | |
| All-cause mortality | 0.004 (0.000 to 0.022) |
| Myocardial infarction | 0.004 (0.000 to 0.022) |
| Death or myocardial infarction | 0.003 (0.000 to 0.016) |
| Subsequent revascularisation | 0.040 (0.008 to 0.104) |

CI: confidence interval

Presented is the between-trial variance $\tau^2$ as a measure of the heterogeneity between trials in the network for each outcome. A $\tau^2$ estimate of 0.04 may be interpreted as a low, 0.14 as a moderate and 0.40 as a substantial degree of heterogeneity between trials. We used a common $\tau^2$ estimate for all comparisons included in an analysis.

**Supplemental Figure 3** **Inconsistency factors for primary analysis of all trials**



**Supplemental Figure 4** **Inconsistency factors for secondary analysis of contemporary trials**



**Supplemental Figure 5** **Inconsistency factors for myocardial infarction and subsequent revascularisation after exclusion of likely sources of inconsistency**



**Supplemental Table 10** — **Primary analysis after exclusion of likely sources of inconsistency**

| | Myocardial Infarction (all trials) | | Subsequent Revascularisation (all trials) | | Subsequent Revascularisation (contemporary trials) | |
|---|---|---|---|---|---|---|
| | Main Analysis | After Exclusion of Likely Sources of Inconsistency* | Main Analysis | After Exclusion of Likely Sources of Inconsistency§ | Main Analysis | After Exclusion of Likely Sources of Inconsistency§ |
| CABG versus Medical Therapy | 0.79 (0.63 to 0.99) | 0.69 (0.55 to 0.85) | 0.16 (0.13 to 0.20) | 0.17 (0.14 to 0.21) | 0.16 (0.12 to 0.21) | 0.19 (0.15 to 0.25) |
| PTCA versus Medical Therapy | 0.88 (0.70 to 1.11) | 0.92 (0.74 to 1.14) | 0.97 (0.82 to 1.16) | 0.97 (0.83 to 1.14) | --- | --- |
| BMS versus Medical Therapy | 1.04 (0.84 to 1.27) | 1.11 (0.92 to 1.33) | 0.69 (0.59 to 0.82) | 0.68 (0.59 to 0.79) | 0.70 (0.57 to 0.87) | 0.68 (0.57 to 0.79) |
| **Early Generation DES** | | | | | | |
| PES versus Medical Therapy | 1.18 (0.88 to 1.54) | 1.21 (0.93 to 1.53) | 0.44 (0.35 to 0.55) | 0.41 (0.33 to 0.51) | 0.43 (0.34 to 0.56) | 0.42 (0.34 to 0.51) |
| SES versus Medical Therapy | 0.94 (0.71 to 1.22) | 0.96 (0.75 to 1.21) | 0.29 (0.24 to 0.36) | 0.27 (0.22 to 0.33) | 0.29 (0.23 to 0.37) | 0.28 (0.22 to 0.34) |
| E-ZES versus Medical Therapy | 0.80 (0.56 to 1.10) | 0.84 (0.61 to 1.11) | 0.38 (0.29 to 0.51) | 0.36 (0.27 to 0.47) | 0.38 (0.28 to 0.52) | 0.36 (0.28 to 0.46) |
| **New Generation DES** | | | | | | |
| R-ZES versus Medical Therapy | 0.82 (0.52 to 1.26) | 0.83 (0.56 to 1.24) | 0.26 (0.17 to 0.40) | 0.29 (0.19 to 0.44) | 0.26 (0.17 to 0.40) | 0.29 (0.21 to 0.33) |
| EES versus Medical Therapy | 0.75 (0.55 to 1.01) | 0.77 (0.85 to 1.00) | 0.27 (0.21 to 0.35) | 0.26 (0.20 to 0.33) | 0.27 (0.20 to 0.35) | 0.26 (0.21 to 0.33) |

CABG=Coronary artery bypass graft surgery; PTCA=Percutaneous transluminal coronary angioplasty; BMS=Bare metal stent; DES=Drug eluting stent;
PES=Paclitaxel eluting stent; SES=Sirolimus eluting stent; R-ZES=Zotarolimus eluting Resolute stent; E-ZES=Zotarolimus eluting Endeavor Stent; EES=Everolimus eluting stent
* after exclusion of GABI, EAST, ERACI II, SoS, Thiele
§ after exclusion of FREEDOM and CARDIA (because of diabetic population) and RESOLUTE CHINA (because of implausible effect)

# References


1. Serruys PW, Foley DP, Suttorp MJ, Rensing BJ, Suryapranata H, Materne P, et al. A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions: final results of the additional value of NIR stents for treatment of long coronary lesions (ADVANCE) study. *J Am Coll Cardiol* 2002;39(3):393-9.

2. Zeymer U, Uebis R, Vogt A, Glunz HG, Vohringer HF, Harmjanz D, et al. Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte. *Circulation* 2003;108(11):1324-8.

3. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. *N Engl J Med* 1999;341(2):70-6.

4. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. *N Engl J Med* 2001;344(15):1117-24.

5. Witkowski A, Ruzyllo W, Gil R, Gorecka B, Purzycki Z, Kosmider M, et al. A randomized comparison of elective high-pressure stenting with balloon angioplasty: six-month angiographic and two-year clinical follow-up. On behalf of AS (Angioplasty or Stent) trial investigators. *Am Heart J* 2000;140(2):264-71.

6. Morrison DA, Sethi G, Sacks J, Henderson W, Grover F, Sedlis S, et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). *J Am Coll Cardiol* 2001;38(1):143-9.

7. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. *N Engl J Med* 1996;335(4):217-25.

8. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* 2009;360(24):2503-15.

9. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). *Lancet* 2005;366(9489):921-9.

10. Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, et al. Drug-eluting versus bare-metal stents in large coronary arteries. *N Engl J Med* 2010;363(24):2310-9.

11. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. *N Engl J Med* 1994;331(8):489-95.

12. Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). *Lancet* 1998;352(9129):673-81.

13. Koning R, Eltchaninoff H, Commeau P, Khalife K, Gilard M, Lipiecki J, et al. Stent placement compared with balloon angioplasty for small coronary arteries: in-hospital and 6-month clinical and angiographic results. *Circulation* 2001;104(14):1604-8.

14. Boudriot E, Thiele H, Walther T, Liebetrau C, Boeckstegers P, Pohl T, et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. *J Am Coll Cardiol* 2011;57(5):538-45.

15. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants. *Lancet* 1995;346(8984):1179-84.

16. Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. *J Am Coll Cardiol* 2010;55(5):432-40.

17. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Comparability of entry characteristics and survival in randomized patients and nonrandomized patients meeting randomization criteria. *J Am Coll Cardiol* 1984;3(1):114-28.

18. Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, et al. Immunosuppressive therapy with oral prednisone to prevent restenosis after PCI. A multicenter randomized trial. *Am J Med* 2011;124(5):434-43.

19. Haude M, Konorza TF, Kalnins U, Erglis A, Saunamaki K, Glogar HD, et al. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients. *Circulation* 2003;107(9):1265-70.

20. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. *Lancet* 2010;375(9710):201-9.

21. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med* 2007;356(15):1503-16.

22. Chen SL, Ye F, Zhang JJ, Liu ZZ, Shan SJ, Sun XW, et al. Different edge effects of paclitaxel- and sirolimus-eluting stents on proximal and distal edges in patients with unstable angina: serial intravascular ultrasound analysis. *Chin Med J (Engl)* 2009;122(14):1603-9.

23. Serruys PW, de Bruyne B, Carlier S, Sousa JE, Piek J, Muramatsu T, et al. Randomized comparison of primary stenting and provisional balloon angioplasty guided by flow velocity measurement. Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) II Study Group. *Circulation* 2000;102(24):2930-7.

24. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. *J Am Coll Cardiol* 2008;52(9):727-33.

25. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). *Lancet* 2003;362(9390):1093-9.

26. King SB, 3rd, Lembo NJ, Weintraub WS, Kosinski AS, Barnhart HX, Kutner MH, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). *N Engl J Med* 1994;331(16):1044-50.

27. Prospective randomised study of coronary artery bypass surgery in stable angina pectoris. Second interim report by the European Coronary Surgery Study Group. *Lancet* 1980;2(8193):491-5.

28. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. *Circulation* 2006;114(8):798-806.

29. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. *J Am Coll Cardiol* 2006;48(12):2440-7.

30. Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O'Shaughnessy C, et al. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. *J Am Coll Cardiol* 2010;55(6):543-54.

31. Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. *N Engl J Med* 1999;341(5):319-27.

32. Rodriguez A, Bernardi V, Navia J, Baldi J, Grinfeld L, Martinez J, et al. Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. *J Am Coll Cardiol* 2001;37(1):51-8.

33. Kim WJ, Lee SW, Park SW, Kim YH, Yun SC, Lee JY, et al. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial. *Circulation* 2011;124(8):886-92.

34. Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. *J Am Coll Cardiol* 2011;58(18):1844-54.

35. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. *N Engl J Med* 2012;367(11):991-1001.

36. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. *N Engl J Med* 2012;367(25):2375-84.

37. Lafont A, Dubois-Rande JL, Steg PG, Dupouy P, Carrie D, Coste P, et al. The French Randomized Optimal Stenting Trial: a prospective evaluation of provisional stenting guided by coronary

velocity reserve and quantitative coronary angiography. F.R.O.S.T. Study Group. *J Am Coll Cardiol* 2000;36(2):404-9.

38. Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). *N Engl J Med* 1994;331(16):1037-43.

39. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. *N Engl J Med* 2005;353(7):663-70.

40. Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. *J Am Coll Cardiol* 2009;53(19):1760-8.

41. Kastrati A, Schomig A, Dirschinger J, Mehilli J, Dotzer F, von Welser N, et al. A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. *Circulation* 2000;102(21):2593-8.

42. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schomig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. *Eur Heart J* 2006;27(3):260-6.

43. Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. *Eur Heart J* 2009;30(8):923-31.

44. Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. *Eur Heart J* 2009;30(20):2441-9.

45. Nishigaki K, Yamazaki T, Kitabatake A, Yamaguchi T, Kanmatsuse K, Kodama I, et al. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. *JACC Cardiovasc Interv* 2008;1(5):469-79.

46. Kinsara AJ, Niazi K, Patel I, Amoudi O. Effectiveness of stents in small coronary arteries. *Am J Cardiol* 2003;92(5):584-7.

47. Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. *Circulation* 2006;114(20):2148-53.

48. Park DW, Kim YH, Song HG, Ahn JM, Kim WJ, Lee JY, et al. Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. *JACC Cardiovasc Interv* 2011;4(10):1096-103.

49. Ahn JM, Park DW, Kim YH, Song H, Cho YR, Kim WJ, et al. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial. *Circ Cardiovasc Interv* 2012;5(5):633-40.

50. Tamai H, Berger PB, Tsuchikane E, Suzuki T, Nishikawa H, Aizawa T, et al. Frequency and time course of reocclusion and restenosis in coronary artery occlusions after balloon angioplasty versus Wiktor stent implantation: results from the Mayo-Japan Investigation for Chronic Total Occlusion (MAJIC) trial. *Am Heart J* 2004;147(3):E9.

51. Hueb W, Soares PR, Gersh BJ, Cesar LA, Luz PL, Puig LB, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. *J Am Coll Cardiol* 2004;43(10):1743-51.

52. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, et al. Coronary intervention for persistent occlusion after myocardial infarction. *N Engl J Med* 2006;355(23):2395-407.

53. Eefting F, Nathoe H, van Dijk D, Jansen E, Lahpor J, Stella P, et al. Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. *Circulation* 2003;108(23):2870-6.

54. Pache J, Dibra A, Mehilli J, Dirschinger J, Schomig A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. *Eur Heart J* 2005;26(13):1262-8.

55. Pan M, Medina A, Suarez de Lezo J, Romero M, Segura J, Martin P, et al. Randomized study comparing everolimus- and sirolimus-eluting stents in patients with bifurcation lesions treated by provisional side-branch stenting. *Catheter Cardiovasc Interv* 2012;80(7):1165-70.

56. Pan M, Suarez de Lezo J, Medina A, Romero M, Delgado A, Segura J, et al. Drug-eluting stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. *Am Heart J* 2007;153(1):15 e1-7.

57. Park SJ, Kim YH, Park DW, Yun SC, Ahn JM, Song HG, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. *N Engl J Med* 2011;364(18):1718-27.

58. Rahel BM, Suttorp MJ, Laarman GJ, Kiemeneij F, Bal ET, Rensing BJ, et al. Primary stenting of occluded native coronary arteries: final results of the Primary Stenting of Occluded Native Coronary Arteries (PRISON) study. *Am Heart J* 2004;147(5):e22.

59. Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. *Circulation* 2006;114(9):921-8.

60. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. *Circulation* 2012;125(16):2015-26.

61. Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. *Lancet* 2012;380(9851):1396-405.

62. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 2002;346(23):1773-80.

63. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. *JAMA* 2006;295(8):895-904.

64. Kimura T, Morimoto T, Natsuaki M, Shiomi H, Igarashi K, Kadota K, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). *Circulation* 2012;126(10):1225-36.

65. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. *N Engl J Med* 2010;363(2):136-46.

66. Xu B, Yang Y, Yuan Z, Du Z, Wong SC, Genereux P, et al. Zotarolimus- and Paclitaxel-Eluting Stents in an All-Comer Population in China: The RESOLUTE China Randomized Controlled Trial. *JACC Cardiovasc Interv* 2013;6(7):664-70.

67. Erbel R, Haude M, Hopp HW, Franzen D, Rupprecht HJ, Heublein B, et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. *N Engl J Med* 1998;339(23):1672-8.

68. Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. *Lancet* 1993;341(8845):573-80.

69. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. *Lancet* 1997;350(9076):461-8.

70. Kelbaek H, Thuesen L, Helqvist S, Klovgaard L, Jorgensen E, Aljabbari S, et al. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. *J Am Coll Cardiol* 2006;47(2):449-55.

71. Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. *J Am Coll Cardiol* 2007;50(17):1627-34.

72. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. *JAMA* 2004;292(22):2727-34.

73. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med* 2003;349(14):1315-23.

74. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. *N Engl J Med* 2005;353(7):653-62.

75. Doucet S, Schalij MJ, Vrolix MC, Hilton D, Chenu P, de Bruyne B, et al. Stent placement to prevent restenosis after angioplasty in small coronary arteries. *Circulation* 2001;104(17):2029-33.

76. Galloe AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. *JAMA* 2008;299(4):409-16.

77. Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. *Lancet* 2010;375(9720):1090-9.

78. Jensen LO, Thayssen P, Hansen HS, Christiansen EH, Tilsted HH, Krusell LR, et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). *Circulation* 2012;125(10):1246-55.

79. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. *JAMA* 2008;299(16):1903-13.

80. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. *EuroIntervention* 2006;2(3):286-94.

81. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. *N Engl J Med* 2010;362(18):1663-74.

82. Grube E, Chevalier B, Guagliumi G, Smits PC, Stuteville M, Dorange C, et al. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberte paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. *Am Heart J* 2012;163(5):867-75 e1.

83. Betriu A, Masotti M, Serra A, Alonso J, Fernandez-Aviles F, Gimeno F, et al. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. *J Am Coll Cardiol* 1999;34(5):1498-506.

84. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. *N Engl J Med* 2011;364(17):1617-25.

85. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. *N Engl J Med* 1994;331(8):496-501.

86. Erne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. *JAMA* 2007;297(18):1985-91.

87. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. *Lancet* 2013;381(9867):629-38.

88. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. *Lancet* 2002;360(9338):965-70.

89. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. *N Engl J Med* 2004;350(3):221-31.

90. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. *Circulation* 2003;108(7):788-94.

91. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. *JAMA* 2005;294(10):1215-23.

92. Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. *J Am Coll Cardiol* 2005;45(2):308-11.

93. Buller CE, Dzavik V, Carere RG, Mancini GB, Barbeau G, Lazzam C, et al. Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). *Circulation* 1999;100(3):236-42.

94. von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. *J Am Coll Cardiol* 2012;59(15):1350-61.

95. Thiele H, Oettel S, Jacobs S, Hambrecht R, Sick P, Gummert JF, et al. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: a 5-year follow-up. *Circulation* 2005;112(22):3445-50.

96. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. *N Engl J Med* 1984;311(21):1333-9.

97. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. *N Engl J Med* 1992;326(1):10-6.

98. Fluck DS, Chenu P, Mills P, Davies A, Street J, Paul E, et al. Is provisional stenting the effective option? The WIDEST study (Wiktor stent in de novo stenosis). Widest Trial Investigators' Group. *Heart* 2000;84(5):522-8.

99. Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. *J Am Coll Cardiol* 2010;56(15):1187-95.

100. Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Ni J, et al. One-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease. *Chin Med J (Engl)* 2006;119(2):165-8.

101. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. *PLoS One* 2013;8(10):e76654.